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INTRODUCTION 
Pulmonary circulation is a low resistance, high compliance 
vascular bed and Only organ to receive entire cardiac output (CO). 
Changes in CO as well as pleural/alveolar pressure affect pulmonary 
blood flow and there by affect the resistance offered by the pulmonary 
vasculature1. 
 Pulmonary hypertension is defined as a condition associated with  
elevation of mPAP > 25 mm Hg at rest. It has multifactorial pathogenesis 
with various aetiologies grouped under five categories2. They are 
classified according to the pathogenic mechanisms involved. 
Differentiation into groups is important as the treatment is given 
according to the group of pulmonary hypertension3.  Its causes significant  
Morbidity and mortality among the affected individuals and hence earlier 
diagnosis and treatment is aimed. 
 Currently haematological issues has been identified to be 
associated with the pathogenesis and progression of disease, especially 
with platelets and its activation resulting in initiation and progression of 
disease. The role of platelets  has been studied extensively and found to 
be associated with idiopathic pulmonary hypertension . Platelets has been 
found to be linked in almost all causes pulmonary hypertension  and the 
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mean platelet volume has been found to be increased in all causes of 
pulmonary hypertension. 
  Thrombocytopenia has been identified as a independent predictor 
of mortality among patients with pulmonary hypertension4. Even though 
the association of platelets in all groups of pulmonary hypertension is 
undoubted, its relation to the severity of pulmonary hypertension and 
effect of treatment for pulmonary hypertension on the platelet indices are 
lacking. 
          Whether platelet indices could be used as a simple surrogate 
marker of severity of hypertension in rural population there by can be 
used to refer patients for higher centres for further evaluation and early 
diagnosis of pulmonary hypertension. 
          Hence in this study we aimed to bring out the platelet morphology, 
count, function and activation using platelet indices as surrogate markers 
in patients with pulmonary hypertension. Its correlation assessed with 
severity of pulmonary hypertension. And also the effect of treatment of  
pulmonary hypertension. 
 
 
 
 
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of various groups of pulmonary 
hypertension among patients attending Rajiv Gandhi government 
general hospital. 
 
2. To access the severity of pulmonary hypertension using 
echocardiogram among patients with pulmonary hypertension. 
 
3. To study the platelet morphology, platelet indices and platelet 
function in various groups of pulmonary hypertension. 
 
4. To study the relationship of platelet indices to the mean pulmonary 
artery pressure and severity of pulmonary hypertension. 
 
5. To study the relationship of platelet function with mean pulmonary 
artery pressure and severity of pulmonary hypertension. 
 
6. To study the effect of treatment on severity of pulmonary 
hypertension and its impact of the platelet indices. 
 
  
 
REVIEW  
OF  
LITERATURE 
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HISTORY OF PULMONARY HYPERTENSION 
 First identified and reported by Ernst Von Romberg in the year 
1891 as pulmonary arterial sclerosis. In 1935 Brenner gave the anatomic 
description. The name primary pulmonary hypertension has been coined 
in 1951 by David Dresdale a research fellow of Cournand and Richards. 
He also studies the hemodynamic variables in pulmonary hypertension.  
In 1958 Heath and Edwards defined the changes in spectrum of 
congenital heart disease and Eisenmenger syndrome described5. Initial 
classification by Edward and Heath in 1958, was a pathological 
classification, dividing into 6 progressive grades starting from persistence 
of foetal pulmonary vasculature to necrotising arteritis. 
 Since then a lot of research and discussion were held by WHO 
conferences and updated and incorporated newer classifications of 
pulmonary hypertension.  After the year 2000 with the diagnosis of 
genetic background for heritable cause of pulmonary hypertension 
namely BMPR2 a lot of newer genes begin to be investigated to be 
associated with pulmonary hypertension even in sporadic cases. With the 
updates, the classification of pulmonary hypertension according to the 
aetiology has gone through lot of frequent changes and in Dana Point 
classification in 2008, pulmonary hypertension is classified into 5 groups. 
The latest classification was given in 2013, conference held at France. 
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REVIEW OF LITERATURE 
DEFINITION: 
 Pulmonary hypertension previously called an orphan disease is 
defined as elevation of mean pulmonary artery pressure (mPAP) of 
25mmHg or greater at rest measured by right heart catheterisation6 
(RHC). This elevation in the pulmonary artery pressure is due to end 
result of diverse diseases. When no cause for the pulmonary hypertension 
could be found, the term Primary Pulmonary Hypertension was used. 
When the cause could be identified, it is called as Secondary Pulmonary 
Hypertension. 
From mid 20th century, lot of research and development of RHC 
techniques by National Institute of Health, NIH, primary Pulmonary 
Registry and by various conferences concluded the clear guidelines for 
classification of Pulmonary Hypertension subcategories.  
PULMONARY VASCULATURE: 
 Pulmonary and Bronchial arteries are the arterial supply to the 
lungs whereas pulmonary and azygous vein form the venous drainage 
channels. Each pulmonary artery usually accompanies the corresponding 
generation of bronchus and divides till the respiratory bronchioles.  
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Pulmonary artery consists of a layer of endothelial cells with 
basement membrane. Adventitia consists of fibrous tissue which is in 
contact with the fibrous connective tissue of the peribronchial region. In 
the media, the pulmonary vasculature has both elastic and muscular 
component7. At its origin, it is more of elastic component which is highly 
distensible for minimal pressure. As the vessel divides and decreases in 
size, it becomes more muscular, about 500 microns in diameter with less 
elastic lamina, thereby less distensible for the same amount of pressure.  
Once the pulmonary arteries divide into arterioles, which is about 
100 microns in diameter, it consists of single layer of endothelium 
covered by thin layer of elastic lamina which then give rise to capillaries. 
Capillaries are formed as only a layer of endothelium attached to 
basement membrane. This network of capillaries are attached to the wall 
of the alveolus. In the periphery of the alveolus, the venules originate 
which ultimately into the main veins8. 
Bronchial artery gives nutrition to airways by ramifying into 
capillary network and drain both into pulmonary veins and systemic 
venous bed. Since it also drain into the pulmonary vein, which carries the 
oxygenated blood, it forms a trivial physiological right to left shunt. 
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Figure 1. Pulmonary Circulation 
 
HEMODYNAMICS OF PULMONARY CIRCULATION 
The normal pulmonary circulation has a high flow, low pressure 
and low resistance.   Normal pulmonary vascular bed offers 10 % less 
resistance as compared to systemic bed. Normal mPAP at rest is 14± 3.3 
mmHg. It is independent of age and ethinicity. Pulmonary hypertension is 
classified as precapillary and post capillary based on Pulmonary Artery 
Wedge Pressure (PAWP)9. If PAWP is 15mmHg or less, it is precapillary 
and 15mmHg or more it is post capillary. Some individuals has elevated 
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mPAP, PAWP and transpulmonary gradient {mPAP- PAWP} greater 
than 12 mmhg showing a mixed picture 
 
Figure 2. Definition of Pulmonary Hypertension Types 
                          
 The Pulmonary Vascular Resistance (PVR) and Total Pulmonary 
resistance (TPR) are important in the hemodynamics and they are 
calculated as ratios: 
 PVR =  (mPAP – PAWP)/CO 
 TPR = mPAP/CO 
The ratios are expressed as mmhg/liter/min, called as a wood unit. 
 With exercises, mPAP increases but is dependent on level of 
exercise and age. Mild exercise in younger individuals increases mPAP 
around 4.8mmhg where as 8.4 mmhg in individuals more than 50 years. 
Hence it becomes difficult to arrive at normal mPAP during exercise. 
There is not enough studies to define it. So the concept of exercise 
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induced Pulmonary Hypertension was abandoned. PVR and TPR and the 
impact of it on exercise, age and posture have been discussed. With 
exercise, the cardiac output increases thereby TPR and PVR decreases. 
For a 85% increase in cardiac output, there is 25% decrease in TPR and 
12% decrease in PVR. As the age increases, there is no significant 
difference, instead the TPR may increase by 17% and PVR remains 
unchanged. 
 
Figure 3. Haemodynamics. 
 
PATHOPHYSIOLOGY: 
 Pulmonary hypertension develops by diverse mechanisms which 
ultimately results in elevation of mPAP. After many studies it has been 
postulated that it is mainly due to the  imbalance between vasodilatation 
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and vasoconstriction mechanisms, thrombosis and remodelling of 
pulmonary arterial walls. Remodelling of pulmonary vasculature occurs 
in all layers of pulmonary arteries with diameter less than 500 micro 
meter and inflammatory cells. Significant role is played by platelets10. 
Early in pathogenesis is vasoconstriction of pulmonary vasculature 
due endothelial dysfunction and abnormal expression of potassium 
channels. Endothelial dysfunction results in decreased production 
vasodilators (nitric oxide and prostacyclin) and increased production of 
endothelin-1 like vasoconstrictors11. These abnormalities results in 
increased vascular tone and promotes remodelling. Other mediators 
involved are bone morphogenetic proteins (BMP), sertonin, angiopoeitin 
and growth factors mainly transforming growth factor –beta superfamily 
 
Figure 4. Pathophysiology 
 
11 
 
 
HISTOPATHOLOGY: 
Histopathology differs in different groups of  pulmonary 
hypertension.
 
Figure 4. Histopathology 
Pulmonary Arterial Hypertension: 
 Small pulmonary arteries less than 500 micrometre showing 
intimal fibrosis, medial hypertrophy, obliteration with thrombotic lesions, 
adventitial proliferation  and perivascular infiltration by inflammatory 
cells and complex lesions namely plexiform lesion.12.  Even though 
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plexiform lesions are not characteristic of PAH they are a form of 
neoplastic growth symbolizing dysregulated endothelial growth. They are 
found in around 90% of cases. 
 
Figure 6. Changes in Pulmonary Vasculature 
 
 Plexiform lesions are like a renal glomerulus with central 
endothelial cells having p27/kip-1 negative and positive cells found in 
peripheral areas. They produce factor 8 vimentin, type 3 nitric acid 
synthase and VEGF receptor Pulmonary veins are free from characteristic 
changes. Presence of plexiform lesions is more specific for pulmonary 
arterial hypertension. 
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Figure 5. Plexiform Histopathology 
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PH Due To Left Sided Heart Disease: 
 Pulmonary veins shows thickening and capillary dilatation , 
alveolar haemorrhage and interstitial edema. Pulmonary artery may be 
affected but not with pathognomonic lesion. 
PH Due To Lung Diseases: 
 Destruction of pulmonary artery with emphysematous or fibrotic 
areas along with other changes like medial hypertrophy and obstruction 
due to proliferation13. 
PH due to CTEPH: 
 Thrombus are the important characteristic finding. Could be of 
various sizes resulting in minimal to total occlusion of pulmonary 
arteries. Collaterals from nearby arteries namely bronchial, costal, 
coronary arteries develop to perfuse the totally occluded areas. 
PH Due To Multifactorial Mechanisms: 
 The pathology is heterogeneous as the causes are heterogeneous 
and they develop due to multifactorial mechanisms. 
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CLASSIFICATION PULMONARY HYPERTENSION 
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GROUP.1 PULMONARY ARTERY HYPERTENSION: 
 They include group of diseases causing a sustained increase of 
mPAP more than 25 mmhg during rest while PCWP or left atrial pressure 
or the left ventricle end diastolic pressure less than 15 mmhg. In addition 
the transpulmonary gradient and the PVR is also increased14. 
Epidemiology: 
 Rare disease with prevalence of 15 to 20 cases seen  per million 
population. 
 
Figure 6. Epidemiology of PAH 
 
Most common cause of pulmonary arterial hypertension is 
idiopathic followed by CTD. Inherited PAH has the least incidence of 
4%.  
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Idiopathic pulmonary arterial hypertension: 
 Previously known as primary pulmonary hypertension where the 
cause of the elevation of mPAP could not be identified. It is the most 
common type among PAH15. Patients were found to be sporadic without 
family history or risk factor. Females are commaly affected with mean 
age at presentation being 37 years. 
Heritable pulmonary arterial hypertension: 
 The first case of heritable PAH was diagnosed by Dresdale and his 
colleagues in 1954. Since then many cases have been reported and lot of 
research has been done on genetic analysis of affected individuals to 
bring out the genes involved. It’s a autosomal dominant triat with 
incomplete penetrance showing the phenomenon of anticipation16.  
 The most studied is the bone morphogenic protein receptor  
2 (BMPR2) belonging to the TGF-beta receptor family and it’s the first 
identified predisposing gene. It is present in chromosome 2 long arm 
(2q31-32)17.  It is said to be responsible for the pulmonary endothelial and 
smooth muscle cell growth and differentiation. The gene is detected in 70 
to 80%of cases with family history and 15 to 20% of sporadic cases. 
Females are commonly affected.  Patients with this mutation are younger 
in age at diagnosis with aggressive course and carry poor prognosis. 
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    Other genes that are involved are activin a receptor type II like 
kinase 1(ALK-1), endoglin,SMAD-9,CAV1- involved in TGF- beta 
signaling pathway18,19.  
Figure 7. Genetics in PAH 
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Drug and toxin induced PAH: 
 With an epidemic outbreak IPAH due to Aminorex fumarate  in 
1960, many structurally linked compunds like fenfluramine , 
dexfenfluramine used as anorexigens  were found to be causing PAH and 
hence withdrawn from market. Some methamphetamines, l-tryptophan, 
rapeseed oil were found to cause PAH. Dasatinib a tyrosine kinase 
inhibitor was also found to cause PAH20. 
 
Figure 8. Drugs Causing PAH 
 
Connective tissue disease and PAH: 
 Associated has been strong with scleroderma spectrum of diseases 
with the prevalence of 8 to 12%. Patients have a poor prognosis with 
treatment when compared to other causes of PAH21. The high risk 
patients could be identified with reduction in carbon monoxide diffusion 
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capacity and echocardiogram screening so as to subject for earlier 
treatment. 
   
 
Figure 9. Screening  for PAH in CTD 
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PAH associated with HIV : 
Rare disease with incidence of 0.5% not being changed with 
extensive use of antiretroviral therapy  not associated with the CD4+ cell 
count or the presence of opportunistic infections22,23. The mechanism 
being not known but association with HIV is clearly established. Hence 
should be suspected in HIV infected patients where any other cause could 
not be identified.  
PAH associated with portal hypertension: 
 Portopulmonary hypertension(POPH)  is the term used when PAH 
develops in patients with portal hypertension. There is no association 
with the severity of liver disease or the portal hypertension  with the 
presence or severity  of  PAH. Seen also in patients with non hepatic 
causes of portal hypertension. . The prevalence is 2 to 6% and it increases 
the perioperative risk in patients undergoing liver transplantation24 
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It should be differentiated from hepatopulmonary syndrome which 
is due to vasodilatation that occurs in pulmonary vasculature causing 
intrapulmonary shunting resulting in hypoxemia and dyspnoea  
 
Figure 10. Port-Pulmoary & Hepato-Pulmonary 
 
PAH associated with Congenital heart disease: 
Seen as a complication due to un corrected congenital heart disease 
with increased pulmonary blood flow and systemic and pulmonary 
shunting. The condition is defined as Eisenmenger syndrome 
characterised by progressive pulmonary vasculopathy with shunt reversal 
resulting in cyanosis. Prognosis is better when compared to other causes 
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of PAH as the right ventricle adaptive response seen in congenital heart 
disease25 
 
Figure 11. Eisenmenger Physiology 
Diagnosis: 
Symptoms:  
 Exertional dyspnoea is the most common presenting sysmptom 
seeni 60% cases. Followed by increased fatigability in 19% cases. 
Syncope seen more frequently in IPAH. As the disease advances patient 
develop syncope, increasing dyspnoea, later right ventricular failure 
24 
 
 
causing abdominal distension , pedal odema26. The symptoms from the 
risk factors causing PH like CTD, COPD, cardiac illness could mask or 
aggravate the symptoms of PH. This has resulted in delay in diagnosis 
with average of 2 years since onset of symptoms.  
Physical signs:   
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Electrocardiogram: 
 Inexpensive and non invasive tool, but not sensitive or specific to 
PH. Common findings are right axis deviation, right atrial and ventricular 
enlargement, sometimes right ventricular hypertrophy with strain 
pattern27  . 
 
Figure 12. ECG in Pulmonary Hypertension 
 
CHEST X RAY: 
 On the lateral view, right ventricular enlargement can be seen. 
Presence of engorged pulmonary artery shadows at the centre with 
pruning of peripheries helps in diagnosis of pulmonary hypertension. 
Pulmonary venous congestion is in left sided heart disease. 
Emphysematous chest showing hyperinflation with flattening of 
diaphragm in cases of COPD28. 
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Figure 13. X - Ray 
 
ECHOCARDIOGRAM: 
 It is a non-invasive screening tool used in suspected pulmonary 
artery hypertension patients. Pulmonary artery pressure determined by 
using Doppler echocardiography more than 35 mmhg is cut off for  
diagnosis of pulmonary hypertension29 
Echocardiogram measures the following parameters: 
1. Pulmonary artery systolic pressure (PASP) 
2. Assessment of left ventricular –systolic, diastolic function and 
valves 
3. Assessment of RV dysfunction 
4. Presence of poor prognostic factors. 
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1.Pulmonary artery systolic pressure (PASP): 
 This depends on the principle that in the absence of right 
ventricular outflow tract obstruction PASP equals the right ventricular 
systolic pressure (RVSP) 
 PASP = RVSP= 4 (VTR)2 + RAP according to the Bernoulli equation  
When  VTR  is less than 2.8 m/s and  PASP less than  36 mmhg  PH is 
less likely. 
2. Assessment of left ventricular function: 
    This helps to find out the cardiac cause for pulmonary hypertension.  
• Left ventricular systolic function: 
a) Fractional Shortening( FS) 
        It is calculated using M mode in echo, measuring the distance 
between the two endocardial  borders above the papillary muscles. 
FS = ( (LVEDD-LVESD) / LVEDD) x 100  
Where LVEDD is the left ventricular diameter end of diastole 
            LVESD is the left ventricular diameter end of systole. 
b) Ejection Fraction: 
     Normal more than 55 
     Mild – 45 to 54 
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     Moderate- 30 to 44 
     Severe less than 30 
• Left ventricular diastolic function: 
     Mitral E and A wave ratio: 
     E wave – diastolic filling of left ventricle before R wave in ECG 
     A wave- atrial filling after P wave  in  ECG 
    Normal E/A ratio is 1.32+  0.42  
• Valves:  
          Mital valve abnormalities are the most common association  
     found with pulmonary hypertension.  
3. Assessment of right ventricular dysfunction: 
• RV hypertrophy- free wall thickness more than 5 mm 
• RV dilatation- mild when RV forms 60 to 100 % of LV area 
 Moderate when RV equals LV 
           Severe when RV more than LV or cardiac apex is by  RV 
• TAPSE- tricuspid annular plane systolic excursion 
• Tricuspid regurgitation –severity 
• Hepatic vein Doppler- reversal of flow shows severe PH 
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5. Poor prognostic factors: 
• Marked right atrial dilataion 
• Pericardial effusion 
• Right ventricular dysfunction 
• D shaped LV 
• Tei index- myocardial  perferomance index 
 
Figure 14. Echocardiogram, A,B,C 
 Dilated Right ventricle compressing the left ventricle causing ‘D’ 
shaped left ventricle30,31. 
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Massive dilatation of right atrium and ventricle with tricuspid valve 
regurgitation 
 
Tricuspid regurgitation jet velocity is found then mPAP is 
calculated using the modifed bernouli equation. This corresponds to RA 
to RV pressure gradient of more than 31 mmHG and the estimated RA 
pressure of 5 mmhg32. 
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VENTILATION – PERFUSION SCAN: 
It is ideal and more specific in diagnosing pulmonary hypertension 
due to CTEPH. In VP scan there will be a segmental or large perfusion 
defects. If CTEPH is still inconclusive, an invasive pulmonary angiogram 
with contrast to be done which shows pouches, webs , bands and even 
complete vascular occlusion33. 
PULMONARY FUNCTION TEST: 
In group 1 PAH, there will be a moderate lung restriction pattern so 
it can be evident in pulmonary function test. In patients with scleroderma, 
there will be a reduced diffusion capacity of carbon monoxide which is a 
warning sign for developing Pulmonary Artery Hypertension. 
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CARDIAC MAGNETIC RESONANCE IMAGING (CMR): 
It is not useful in diagnosing PAH, but helps in assessing the right 
ventricular function and also in assessing the CHD. Right ventricular 
ejection fraction less than 35%  on CMR is predictive of mortality 
OXIMETRY: 
A overnight oximetry is done in identifying the patient with 
obstructive sleep apnea. Formal polysomnography is done in patients 
with desaturation at night. 
FUNCTIONAL ASSESSMENT: 
Functional assessment following disease progression or the 
treatment response are based on the 6 Minute Hall Walk (6MW). It is one 
of the prognostic indicator for assessing the patients with PAH. It is still 
on research but it is still the primary endpoint in clinical trials in 
assessing the PAH3435. 
WHO gave the functional classification of patients for pulmonary 
hypertension similar to NYHA. Is useful in initial assessment , further 
prognosis and the response to treatment.  
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 The other important way of assessing the exercise capacity and gas 
exchange is by doing cardiopulmonary exercises. Peak systolic blood 
pressure less than 120mmHg and peak oxygen uptake less than 10.4 
mL/Kg/min is a poor prognostic indicator 
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RIGHT HEART CATHETERISATION: 
 It is the invasive procedure done at the end, if all other non-
invasive procedure proved to be inconclusive but still PAH could not be 
ruled out. 
 
Figure 15. Right Heart Catheterisation 
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 The measurements that are done during the RAH are: 
1. Oxygen saturation in SVC, IVC, pulmonary and systemic arteries 
2. Right Atrial and Right Ventricular pressure 
3. Pulmonary artery pressure 
4. Left side filling pressure 
5. CO/ cardiac index 
6. PVR 
7. Systemic blood pressure 
8. Heart rate 
9. Response to acute vasodilators 
The commonest mistake in diagnosing the PAH is misinterpreting 
the PAWP values. It should be measured at different segments of the 
pulmonary vasculature and at the end expiration. Acute vasodilator 
testing should be performed in the patients with IPAH36.  
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TREATMENT: 
 Goals of the treatment in PAH are to improve the symptoms, right 
ventricular function, hemodynamics, exercise tolerance and thereby 
improving the survival. 
37 
 
 
      
 
Figure 16. Treatment Algorithm 
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GENERAL MEASURES: 
 Graded low level aerobic exercises are allowed to do but heavy 
physical exertion and isometric exercises should be avoided.  
 Intensive pulmonary rehabilitation proved to be useful in some 
patients. 
 Oxygen therapy in order to maintain the saturation at 92% or 
above.( it may not be possible in patients with intracardiac 
shunting) 
 Sodium restricted diet (< 2400 mg/day) is advisable especially in 
patients with right heart failure. 
 Immunisation against influenza and pneumococcal are mandatory. 
 Hemodynamic fluctuations during pregnancy is very difficult to 
manage and maternal mortality reaches almost 50%. Hence better 
to terminate pregnancy in patients with PAH. 
 
ANTICOAGULANTS AND DIURETICS 
 Anticoagulants are useful in treating patients with PAH, 
particularly with Idiopathic PAH. Warfarin is the prescribed drug and the 
dosages are adjusted in such a way that INR is maintained between 1.5 
and 2.5.37 
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Diuretics are used in patients with right heat failure with volume 
overload. Care has to be taken that there should not be any electrolyte 
imbalance or deteriorating renal function.  
CALCIUM CHANNEL – BLOCKERS 
 It is helpful in those patients with PAH who are good responders to 
the acute vasodilator testing. Positve response to this test is defined as fall 
in mPAP of atleast 10mmHg to a mPAP of 40mmHg or less with 
unchanged or increased CO. those patients who met this criteria but does 
not improve with this drug should not be considered as chronic 
responders and should find an alternate PAH therapy. IPAH in some 
patients (< 7%)  responds to calcium channel blockers. Drugs used are 
nifedipine, diltiazem and amlodipine38. Verapamil should be avoided 
because of its negative inotropic effects. 
PROSTANOIDS 
The absent or reduced prostacyclin synthase in PAH is one of the 
important pathophysiology mechanism. Prostacyclin I2, which is a 
vasodilator with antiproliferative effects are not synthesised in PAH39. 
Many treatment protocols are aimed at it. Commonly used prostanoids 
are : 
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 Epoprostenol – continuous intravenous, dosage to start with 2 
ng/kg/min and can be titrated upward with maximum dosage of 25 
– 40 ng/kg/min40,41,42. 
 Treprostinil – continuous subcutaneous, intravenous and 
intermittent inhaled. The dosage is maximum of 75 – 
150ng/kg/min43,44,45. 
 Iloprost – intermittent inhaled46. 
 Inhaled prostacyclin analogues shows superior results in improving 
pulmonary hemodynamics and functional capacity and also in reducing 
the worsening of pulmonary hypertension. 
ENDOTHELIN RECEPTOR ANTAGONIST: 
 The Endothelin-1 is  a potent vasoconstrictor which contributes to 
the pathogenesis of PAH. The commonly used endothelin receptor 
antagonist used in the treatment of PAH are: 
1. Bosentan – It is helpful and highly effective in patients with 
congenital systemic-to-pulmonary shunts and Eisenmenger 
physiology47,48,49. After drug therapy, there is improvements in 
PVR, mPAP and 6MW distance and also there is no worsening of 
oxygen saturation. Liver function to be monitored. 
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2. Ambrisentan – Same as bosentan. Liver dysfunction is not so 
significant. 
3. Macitentan – It is  used as a dosage of 3mg  or 10 mg daily50. 
PHOSPHODIESTERASE INHIBITORS: 
 The derangements of cyclic Guanosine Monophosphate (cGMP) 
pathway due to reduced NO synthesase is the another pathogenesis in 
PAH. PDE5 inhibitor drugs like Sildenafil 20mg thrice daily helps in 
inhibiting the hydrolysis of cGMP and thereby improving the symptoms 
of PAH51. Tadalafil is another drug which is used as 40mg single dose52. 
 
 
Figure 17. Sites of drug action in Pulmonary Vasculature 
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SOLUBLE GUANYLATE CYCLASE STIMULATORS: 
 Riociguat53,54,55, it directly stimulates the soluble guanylate cyclase 
and increases the sensitivity of it to NO. it should not be used along with 
PDE5 inhibitors. 
DRUGS ON RESEARCH: 
 Selexipag – Selective prostacyclin receptor agonist. 
Imatinib – Used  in refractory PAH and it improves PVR and CO. 
Nilotinib, serotonin transport inhibitor escitalopram, oral 
prostacyclin analogues Beraprost, inhaled NO and sodium nitrate 
preparations are ongoing trials 
INTERVENTIONAL THERAPIES: 
1. Atrial septostomy – It creates an increased right to left interatrial 
shunt and decreases the right heart filling pressure and thereby 
improving the symptoms of PAH. 
2.  Graded balloon dilatation of the fossa ovalis is the another 
procedure 
3. Transplantation – lung or heart lung transplantation is used as a 
final resort. 
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GROUP 2. PH BY LEFT SIDED HEART DISEASE: 
 Presence of chronic left sided ventricular systolic or diastolic 
dysfunction or valvular  lesions results in persistent elevation of left atrial  
pressure there by causing passive backward transmission of pressure to 
pulmonary veins . Characterised by elevation pulmonary artery wedge  
pressure more than 15 mmhg, with normal transpulmonary gradient and 
pulmonary venous resistance.  
 Common causes are mitral and aortic valve disease, pericardial 
disease, cardiomyopathies, left ventricular dysfunction age related 
changes.  Out of all heart failure, preserved ejection fraction (HFpEF) is 
now found to be more common cause. 
Figure 18. Management of Group 2 PHT 
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 Right ventricle is not affected in the early stage of the disease. It 
adapt itself to the elevated afterload with hypertrophy. If the disease 
progress further, it may go for right ventricular dysfunction. Hence right 
ventricle is the lastly affected in pulmonary venous hypertension. 
DIAGNOSIS: 
HFpEF is the commonest cause and is often mistaken with IPAH in 
the diagnosis56. It occurs in patients with older than group 1. Orthopnea, 
paroxysmal nocturnal dyspnea are pathognomonic 
Figure 19. Difference between PAH & HFpEF 
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Chest X Ray – pulmonary vascular congestion, interstitial edema 
on radiograph 
CT Chest – Mosaic perfusion pattern and ground glass opacities 
ECG – Left ventricular and atrial enlargement, atrial fibrillation. 
Echocardiogram – Left ventricular hypertrophy,  left atrial 
enlargement and Doppler showing diastolic dysfunction. 
Two types of hemodynamic profiles are seen: 
1. Elevation in Pulmonary Arterial Pressure with only a slight 
increase in transpulmonary gradient (mPAP - PAWP). 
In preserved right ventricle, a high systolic pressure is generatd to 
maintain adequate forward blood flow. So moderate degree of PH 
is characteristic and favourable. 
2. Some patients will have elevated pulmonary arterial pressure  due 
to reactive pulmonary vasoconstriction. They will have 
characteristic elevation in pulmonary artery diastolic pressure. 
TREATMENT: 
1. Treat the underlying cause. 
2. Blood pressure to be controlled. 
3. Volume management. 
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4. Sodium restriction diet. 
5. Comorbid diseases like obesity. Diabetes to be addressed. 
6. Maintain sinus rhythm as these patients will not tolerate atrial 
fibrillation. 
7. No role in PAH specific therapy. 
GROUP 3: PULMONARY HYPERTENSION CAUSED BY 
CHRONIC RESPIRATORY DISEASES: 
 In the chronic lung diseases, there will be alveolar hypoxia, leading 
to pulmonary vasoconstriction and remodelling resulting in pulmonary 
hypertension. Generally, in respiratory pathology, mPAP is less than 
40mmHg i.e., mild to moderate pulmonary hypertension. Severe 
pulmonary hypertension is rare57,58. Progression of natural history of 
pulmonary hypertension is low in patients with COPD (0.5mmHg/year). 
Figure 20. COPD & PH 
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Echocardiographic screening in patients with COPD is difficult and 
hence the severity could not be assessed. mPAP  is inversely correlated 
with PaO2. With the knowledge of FEV1, PaO2, and mPAP, patients could 
be classified into 4 groups namely, 
1. Normal mPAP, moderately decreased FEV1 and PaO2. 
2. Moderate mPAPand PaO2,  severely decreased FEV1. 
3. High mPAP, Severely decreased  PaO2, FEV1. 
4. Severe mPAP and severly decreased PaO2 and moderate reduction 
in FEV1. 
The last group has high FEV1 and mPAP but lower PaO2 than the 
other groups suggesting alteration in pulmonary vasculature. These 
patients may have other comorbid conditions favouring diastolic and 
systolic dysfunction, obstructive sleep apnoea etc. These patients have 
severe exertional dyspnea, poor prognosis than other COPD patients59,60. 
DIAGNOSIS: 
 As patients have nonspecific signs and symptoms pertaining to 
cardiac and respiratory pathology, it is difficult to differentiate both. 
Spirometry, arterial blood gas analysis, diffusion capacity for carbon 
monoxide are important for diagnosis. BNP is also elevated but it can 
occur in both left heart and right heart failure.Doppler echocardiography 
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is suboptimal in diagnosing COPD induced PH. However the gold 
standard in diagnosing PH is RHC, which determines the precapillary PH 
and the hemodynamic severity excluding the post capillary component. 
Always it is important to keep in mind the comorbid conditions like left 
heart failure, obstructive sleep apnoea etc as they also contribute to the 
clinical findings. 
Figure 21. PH due to Cardiac & Lung Disorder 
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TREATMENT: 
Smoking cessation is very important and it is first and foremost to 
prevent further progression of the disease. Long term Oxygen therapy is 
helpful and it results in decreased mPAP.pharmacological drugs like 
calcium channel blockers, PDE5 inhibitors are tried but they have 
deleterious effect in the alveolar gas exchange. The ideal management in 
the end stage disease is lung transplantation. Even PH due to other lung 
disease like sarcoidosis, Interstitial lung disease, Pulmonary Langerhans 
cell histiocytosis and lymphangioleiomyomatosis all lead to end stage 
lung disease will warrant a lung transplantation. 
GROUP 4. CHRONIC THROMBOEMBOLIC PULMONARY 
HYPERTENSION (CTEPH): 
It is a curable form of pulmonary hypertension which often 
requires surgical management. It is diagnosed by certain findings which 
persists after 3 months of continuous anticoagulant therapy. These 
findings are, at least one segmental perfusion defect seen in CT 
angiography or lung scanning and presence of precapillary type of 
pulmonary hypertension. CTEPH  is due to pulmonary embolism 
obstructing the main pulmonary arteries. Incidence being 3 to 30 million 
population is often misdiagnosed. Error mainly due to referral bias, 
difficulty in diagnosis of pulmonary hypertension in acute pulmonary 
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embolism due to lack of specific symptoms in the acute stage. Acute 
venous thromboembolism is an independent risk factor. Prothrombotic 
factors lupus anticoagulant, antiphospholipid antibodies, factor 8 are 
associated with it. Due to hyper coagulation, increase platelet count and 
inability to cleave fibrinogen, contribute to the obliteration of pulmonary 
arteries. Median age at diagnosis is 63 years, occurring equally in both 
sexes. 
DIAGNOSIS: 
Non-specific signs and symptoms pertaining to right sided heart 
failure like oedema, abdomen distension is found. In contrast to IPAH, 
these patients have haemoptysis, disease is suspected with the presence of 
risk factors. Imaging modalities like CT, ventilation perfusion scan aid in 
the diagnosis. Presence of atleast one defect involving more than half of a 
segment of  lung is diagnostic in ventilation perfusion scan. But some 
patients may have nonsegmental and smaller defects especially in PAH 
and PVOD. 
RHC will show prcapillary PH. The prognostic indicator after 
surgery is the PVR. Contrast enhanced CT shows, stenosis, complete 
obstruction, arterial wall irregularities, pulmonary artery webs and bands. 
Side selective pulmonary angiography in both anteroposterior and lateral 
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views helps in assessing the involvement of the proximal segment and 
evaluating the surgical accessibility. 
TREATMENT: 
Surgery is the treatment of choice in CTEPH. Embolectomy and 
pulmonary endarterectomy are the surgical procedures done in CTEPH. 
Based on the specimen it can be divided into four types: 
Type I : Involving main and lobar pulmonary arteries with red 
thrombus and white obstruction. 
Type II: Intimal thickening and fibrosis in proximal to segmental 
arteries. 
Type III: Thickening, fibrosis and intimal webbing involving distal 
segmental and subsegmental arteries 
Type IV: Microscopic distal arteriolar vasculopathy without visible 
thrombus. Type IV is not operable. 
Operable Criteria: 
• NYHA functional class II, III or IV 
• Preoperative PVR more than 300 dyne-sec.cm-5 
• Surgical accessibility of thrombi in main, lobar or segmental 
arteries 
• Reasonable relationships to hemadynamic severity 
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• Absence of severe comorbid disease  
After surgery most of the patients are relieved of symptoms and 
anear normal haemodynamic stability occurs. Medical treatment also 
attempted in CTEPH61 and they are lifelong anticoagulants with vitamin 
K antagonists, diuretics, oxygen supplementation. Soluble guanylate 
cyclase stimulator, riociguat helps in improvement of 6MW and PVR. 
GROUP 5. PH WITH UNCLEAR OR MULTIFACTORIAL 
CAUSE: 
 Multiple mechanisms contribute to the pathogenesis of pulmonary 
hypertension  like hyperdynamic circulation causing congestive cardiac 
failure, intrapulmonary haematopoiesis can cause obstruction to 
pulmonary arteries, porto pulmonary hypertension are seen following 
certain hematologic disorders especially with myeloproliferative  
diseases.  splenectomised individuals either post traumatic or following 
hematologic disorders favours development of distal CTEPH or IPAH 
 Some of haemolytic anaemia like sickle cell disease62, beta thalassemia 
are associated with PH. They can cause post capillary PH due to 
hyperdynamic circulation or precapillary PH by producing pulmonary 
vascular remodelling. Most commonly associated with sickle cell disease 
the incidence being 6%.  
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Systemic disorders: 
Sarcoidosis: 
 It is a chronic granulomatous disease of unknown etiology.  It 
causes fibrosis of the pulmonary capillary bed resulting in hypoxia. As 
the severity is out of proportion to the degree of destruction  other causes 
were considered like cardiac sarcoidosis,  mediasternal lymphadenopathy 
causing compression of pulmonary vessels,  etc. Treatment  tried with 
steroids63. 
Pulmonary Langerhans cell histiocytosis: 
 Even though a rare disease it is seen in younger individuals with 
smoking history.  Causes parenchymal destruction  and vasculopathy 
changes. Poor prognosis. Treatment being lung transplantation64 
 Other systemic disoreders like lymphangioleiomyomatosis  and 
Neurofibromatosis are also associated with PH with multiple unclear 
mechanisms of causation. 
Metabolic disorders: 
 Enzyme deficiency disorders like type 1 a glycogen storage disease 
due to glucose 6 phosphate deficiency, Gauchers disease due to 
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lysosomal B glucosidase deficiency can cause thromboembolic  or 
restrictive lung disease attributing to pulmonary hypertension 
Miscellaneous: 
Rare conditions like pulmonary artery sarcomas, metastatic tumor 
emboli from breast,lung or gatric cancers, fibrosing alveolitis, end stage 
liver disease on lomg term haemodialysis are also associated with 
pulmonary hypertension. 
Platelets: 
 They are anucleate small (3.0 x0.5µm) discoid shaped cells, 
fragmented from megakaryocytes stimulated by thrombopoietin produced 
by liver65. These stimulated megakaryocytes undergo endomitosis and 
there by sends cytoplasmic projections called proplatelets. Each 
megakaryocyte gives rise to 1000 to 2000 platelets. Normal paltelets 
cytoplsmic volume is 7fl. Younger platelets are larger than those present 
in circulation due to abundant cytoplasm. They are some times counted 
along with RBCs due to their larger size. Half life of platelets is 8 to 10 
days. 
55 
 
 
               
Platelets in various stages of activation from rest, partial to full     
actiavtion from left to right. 
 In peripheral smear stained by wright’s stain, they appear as blue 
grey cells with purple red granules measuring one tenth of size of red 
blood cells. Normal thrombocyte count is 1,50,000 to 4,00,000 per µl. 
One third of the platelet pool is sequested inside the spleen and released 
into circulation in times of demand. It is referred as the marginal pool. 
Epinephrine causes release in times of stress. Aged platelets are destroyed 
in spleen.Platelets contain numerous granules which are released on 
activation. 
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Alpha granules : 
 Contain vwf, fibrinogen, procoagulant factor v, growth factors 
PDGF and TGF- beta, platelet factor 4(PF4)  also called as heparan. PF4 
functions as a heparan inactivator by binding with the endogenous 
heparan sulphate at the site of injury and helps in clot formation. Growth 
factors play important role in smooth muscle, fibroblast proliferation and 
repair. 
Dense granules: 
  Each platelet contains 3 to 8 dense granules. They are secreted 
rapidly into the circulation when activated. They contain ADP, calcium 
and serotonin. ADP is important in activation of platelets and causes 
recruitment of other platelets. Serotonin increases vascular tone by 
causing vasoconstriction. Calcium causes actin- myosin chain contraction 
in the cytoskeleton of platelets causing shape change. It also helps in 
coagulation cascade and collagen crosss linking. In addition calcium 
forms a co factor for phospholipase c , enzyme involved in formation of 
arachidonic acid and further reactions leading to formation of 
thromboxane A266. 
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 Platelets are seen as individual cell circulating inside blood vessels 
not interacting with other platelets or cells. But equipped with extensive 
capacity to adhere to the vessel wall once injured  and aggregate with in 
themselves in order to seal the breech with platelet plug( primary 
haemostasis) and also in conversion of fibrinogen to fibrin strands 
mediated via thrombin to reinforce the platelet plug( secondary 
haemostasis). 
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Platelet adhesion: 
 Vascular injury results in exposure of sub endothelial collagen and 
VWF. Clotting mechanisms are activated once factor vii comes in contact 
with the exposed collagen and tissue factor. Platelets also react by 
attaching to subendothelial collagen and VWF via glycoprotein receptors 
namely GPIa/IIa and GPIb/ix respectively present in the surface platelets. 
This process is referred to as adhesion. This results in release of platelet 
granules and fibrinogen and VWF high affinity receptor GPIIb67,68. 
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Platelet aggregation: 
 The adherent platelet now attracts near by platelets by forming 
fibrinogen and VWF cross bridge. In addition activated platelet surface 
expose phosphatidyly residues for the vtamin k dependent clotting factors 
namely II,V,VII,X  to act. The coagulation cascade occurs on the surface 
of platelet forming thrombin 
 
Platelet indices: 
 They are markers for the early diagnosis of thrombo embolic 
diseases. Most of them were used as a surrogate marker for platelet 
activation 
1. Mean platelet volume -MPV 
2. Platelet distribution width- PDW 
3. Platelet large cell ratio- P- LCR 
4. Plateletocrit 
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Mean platelet volume: 
 Gives the average size of the platelets found in the blood. 
Calculated by automated counters by using optical light scatter 
techniques. 
MPV :  plateletcrit/number of platelets  
 Similar to the MCV calculated in red cell indices. The normal 
value range is 7 to 11 fl. It is influenced by addition of anticoagulants and 
delay in time from sampling to analysis. With EDTA 7.9% increase in 30 
min to 13.4% increase after 24 hrs of sample collection. This could be 
minimised by using citrate tubes and standardizing time delay. 
Larger platelets are younger more reactive and contains more 
thrombogenic factors. MPV is inversely proportional to the platelet count. 
In patients with severe thrombocytopenia less than 20,000 MPV was 
found to be more valuable marker of haemorrghic episode rather than the 
count. 
Increase in MPV has been associated with peripheral immune 
destruction disease where the marrow response is good to release younger 
and larger platelets. Eg- inflammatory bowel disease, immune 
thrombocytopenic prpura, pre eclampsia. 
Bernard soulier syndrome is associated with large platelet. 
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Lower MPV is associated with marrow disease  
MPV has also been found to be increases in patients with 
pulmonary hypertension, stroke, myocardial infarction and diabetes 
patients. 
Thrombocytopenia with low MPV- aplastic anemia. 
Platelet distribution width: 
Simple and specific marker for activation of coagulation. 
Size of distribution curve in Fl at 20%level of peak. More reliable 
marker to distinguish relative thrombocytosis from increase due to 
myeloproliferative disorders. 
Normal value range- 11to 18  
Other less commonly used indices are mean platelet component 
and mean platelet mass used to detect platelet activation. 
Markers of platelet activation: 
 Increase in MPV and PDW are suggested as they signify platelet 
swelling and pseudopodia formation. 
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PULMONARY HYPERTENSION – ROLE OF PLATELETS  
Pulmonary artery hypertension and platelet are related and it has 
been proved in various clinical trials. Platelet activation is seen in 
pulmonary arterial hypertension but whether the platelet activation is seen 
in other etiological factors leading to pulmonary hypertension is less well 
studied69. Platelet abnormalities leads to platelet activation and it releases 
various mediators which leads to progression of pulmonary hypertension. 
Once the platelets are activated, they cause thrombotic obstruction of the 
pulmonary arteries which increases the pulmonary artery pressure and as 
well as the vessels undergo remodelling in a negative way to further 
worsen the clinical condition of pulmonary hypertension. Whether the 
platelets are abnormally activated in pulmonary hypertension or the 
platelets activation causes pulmonary hypertension is still unclear. 
Anyhow, activated platelets worsen the clinical scenario of the pulmonary 
hypertension. 
These platelets when they travel along the pulmonary vasculature 
in pulmonary arterial hypertension, they contribute to thrombin and clot 
along the vessels70. They also release their mediators like serotonin and 
platelet derived growth factors which causes smooth muscle cell 
proliferation and vessel medial hypertrophy leading to occlusion of the 
vessel and thereby increasing the chances of worsening pulmonary 
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hypertension. Studies have shown that, the platelets in pulmonary 
hypertension have lesser serotonin levels compared to normal individuals 
indicating that these abnormally activated platelets are degranulated and 
released the serotonins.  
Abnormally activated platelets are diagnosed by the Mean Platelet 
Volume (MPV). The MPV is increased in the pulmonary hypertension. It 
is very high in Pulmonary arterial hypertension and left heart failure 
leading to pulmonary hypertension than other aetiologies like right heart 
failure, obstructive sleep apnoea etc leading to pulmonary hypertension.   
Large platelets are highly reactive and more thrombotic than 
normal one. These large platelets are increased in pulmonary arterial 
hypertension. They also contain more dense granules and high levels of 
serotonin and hence release these by products in higher amount. These 
large platelets also causes increased platelet aggregating activity which 
further worsen the condition71. 
Increased mean platelet volume means increased platelet activity. 
However the increase in mean platelet volume does not correlate with the 
total thrombocyte count. So it indicates that there is a primary 
abnormality rather than a response to total thrombocyte number. 
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In pulmonary hypertension due to COPD, LVF etc there is no 
primary pathology in pulmonary arterial system but however when the 
disease progresses further it causesarterial vasoconstrictive response and 
arteriole changes which are partly because of the platelet activation. 
Hence the mean platelet volume is increased in these aetiology leading to 
pulmonary hypertension. But platelet activation directly is not related to 
the disease. So the mean platelet volume raise is not as high as those 
cases with primary pulmonary arterial hypertension but there is a 
definitive raise in the mean platelet volume. All these findings implies 
that platelet activation is seen in all causes of pulmonary hypertension 
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either directly or indirectly and it also aid in the progression of the 
disease in spite of it is not the cause for it. 
Systemic hypoxaemia and metabolic acidosis stimulates platelet 
activation in COPD leading to pulmonary hypertension. Studies shown 
that inducing hypoxemia in healthy individuals does not activate platelets 
whereas, patients with pulmonary hypertension and hypoxemia in COPD 
showed marked increase in mean platelet volume and altered platelet 
morphology with more number of large platelets. These results indicate 
that platelet activation occurs in pulmonary hypertension of all 
aetiologies and not only with the pulmonary hypertension.  
Increased shear forces of platelets in pulmonary vascular bed in 
pulmonary hypertension of any cause, leads to activation of platelets, 
changing the antithrombotic properties of vascular endothelium and 
increased vessel wall and platelets interactions. 
  
 
MATERIALS  
AND  
METHODS 
  
66 
 
 
MATERIALS AND METHODS 
Source of data: 
 Patients admitted in Rajiv Gandhi Government General hospital 
who on evaluation diagnosed to have pulmonary hypertension using 
echocardiographic evidence are explained about the study in their own 
language. Patients willing to participate are included into the study after 
getting consent for the study. 
Study design: 
 Observational study 
Study centre: 
 Institute of internal medicine  
Rajiv Gandhi Government General hospital, Chennai -600003 
Duration of study:  
 6 months from April 2015 to September 2015 
Inclusion criteria: 
 All patients with echocardiographic evidence of pulmonary 
hypertension age more than 18 yrs willing to participate in the study were 
included. 
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Exclusion criteria: 
• Patients already under treatment of anti coagulants 
• Presence of liver disease 
• Haematological malignancies 
• Platelet function disorders 
• Fevers causing thrombocytopenia 
• Pregnant patients 
• Renal failure patients on haemodialysis 
 
Sample size: 
 104 patients were included in the study 
 
Data collection method: 
 Patients admitted with symptoms, signs suggestive of pulmonary 
hypertension on evaluation with echocardiogram diagnosed to have 
pulmonary hypertension are subjected to thorough 
1. History of presenting illness 
2. Past history 
3. Clinical examination 
4. Systemic examination 
5. Investigations: 
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• Complete blood count done by automated analyser  
• Bleeding time 
• Clotting time 
• Peripheral smear 
• ECG 
• Chest x ray 
• Echocardiogram done by cardiologist. 
 
METHODOLOGY: 
Presenting complaints: 
 A detailed history of presenting illness collected to functionally 
classify the severity of pulmonary hypertension using WHO scales. 
Main complaints are, 
• Breathlessness- onset, duration , aggravating , relieving factors, 
associated symptoms, orthopnoea, PND  and grade of 
breathlessness 
• Chest pain- site of pain, radiation, onset, duration , aggravating , 
relieving factors, associated symptoms   
• Abdomen distension  
• Pedal odema 
• Jaundice 
• Bleeding manifestation 
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Past history: 
 Diabetes mellitus , hypertension, coronary heart disease, stroke , 
renal disease  
 General examination : pallor, icterus, cyanosis, clubbing, pedal 
odema, lymph node, jugular venous pulse 
Systemic examination : 
Cardiovascular system: palpable p2, Early systolic click, Left 
Parasternal heave, JVP with prominent a, v wave,  Holosystolic murmur 
of TR, Diastolic murmur of pulmonary regurgitation  
Abdomen: 
 Hepatomegaly, pulsatile liver, aacities 
Respiratory system:  
      Features of volume loss, coarse leathery crackles, hyperinflated lung 
Investigations: 
Complete blood count: 
 Around 2 ml of intravenous sample obtained and collected in 
EDTA test tubes and care taken to process all the collected sample in 
automated analyser with one hour of collection in order to avoid the 
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effect of time on the calculated MPV and to obtain comparable sample. 
The automated analyser uses optical light scatter method to access the 
volume of the cells. RBC indices, WBC with differential count , platelet 
indices are all obtained at the same time. 
Bleeding time: 
 Clotting time 
Peripheral smear: 
 ECG:  RVH with strain,  right axis deviation, complete or 
incomplete RBBB, ratio of R wave to S wave more than 1 in lead V1.   P 
pulmonale in lead II  
Chest X ray: 
Echocardiogram:   
 1.MEASUREMENT OF TR JET VELOCITY 
2.ASSESSMENT OF RIGHT VENTRICULAR FUNCTION 
3.ASSESSMENT OF LEFT VENTRICULAR FUNCTION 
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OBSERVATION AND RESULTS 
 In our study 104 patients were enrolled out of them 37(36.5%)  
belong to the age group 41 – 50 years. Least number of patients belong to 
the age group 20 – 30 years. 
AGE GROUP 
 
AGE GROUP NO. OF PATIENTS PERCENT 
20-30 8 7.7 
31-40 22 21.2 
41-50 37 35.6 
51-60 23 22.1 
ABOVE 60 14 13.5 
Total 104 100.0 
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Gender 
GENDER PATIENT PERCENT 
MALE 56 53.8 
FEMALE 48 46.2 
TOTAL 104 100.0 
 
In this study, male and female incidence are almost equal with 
incidence of male being slightly higher.  
54%
46%
Gender
Male
Female
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Pulmonary Arterial Hypertension:Among  patients with PAH  
idiopathic causes are common. Seen mostly in females. 
Aetiology: 
 Out of 104 patients, 27 patients due to old pulmonary tuberculosis 
and COPD form the major cause. 
ETIOLOGY NO. OF PATIENTS PERCENT 
ASD 2 1.92 
BRONCHIECTASIS 5 4.81 
CHEST DEFORMITIES 3 2.88 
CTEPH 4 3.85 
ILD 5 4.81 
LV SYS DYFN 10 9.62 
LV DIA DYFN 6 5.77 
OLD PT/COPD 27 25.96 
OSA/MORBID OBESITY 9 8.65 
OTHERS 2 1.92 
PAH-CTD 6 5.77 
PAH-HIV 3 2.88 
PAH-IDIOPATHIC 5 4.81 
PDA 1 0.96 
VALVULAR HD 11 10.58 
VSD 5 4.81 
TOTAL 104 100 
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WHO functional class: Most of the patients admitted  43(41.3%)  where 
in functional class 3. 
Functional class No. Of Patient Percent 
Class I 0 0 
Class II 23 22.1 
Class III 43 41.3 
Class IV 38 36.5 
Total 104 100.0 
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41%
37%
Functional class
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Classification of Pulmonary Hypertension 
Groups No. Of Patients Percent 
I 13 12.5 
II 35 33.7 
III 50 48.1 
IV 4 3.8 
V 2 1.9 
Total 104 100.0 
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SEVERITY GRADE OF PULMONARY HYPERTENSION:  
graded as mild, moderate and severe depending  upon mPAP 
 
17%
51%
32%
Severity
MILD
MODERATE
SEVERE
 
Severity No. of patients Percent 
MILD 18 17.3 
MODERATE 53 51.0 
SEVERE 33 31.7 
Total 104 100.0 
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PERIPHERAL SMEAR:  
 Most of the patients 52 (50%) had normal smear 
PERIPHERAL SMEAR 
NO. OF 
PATIENTS 
PERCENT 
LARGE PLATELETS 51 49.0 
NORMAL 52 50.0 
THROMBOCYTOPENIA 1 1.0 
TOTAL 104 100.0 
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VALVES:  
 Mild TR seen 34(32.7%) of the patients.  
VALVES 
NO OF 
PATIENTS 
PERCENT 
 
MILD MR 14 13.5 
MILD TR 34 32.7 
MODERATE MR 9 8.7 
MS MODERATE 5 4.8 
MS/MR 2 1.9 
NORMAL 28 30.8 
SEVERE MS 5 1.0 
TR MODERATE 1 1.0 
VSD MILD MR 2 1.9 
VSD MILD TR 3 2.9 
TOTAL 104 100.0 
 
REVIEW AFTER 2 MONTHS OF TREATMENT: 
 All enrolled patients are given treatment according to the group 
which they belong to and review after 2 months. The effect of treatment 
assessed in terms of functional class, hemogram and echo  
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Who functional class: 
 
Functional class   
1 2.00 3.00 4.00 
Initial  assessment 0(0.00%) 23 (22.1%) 43(41.3%) 38(36.5%) 
After 2 months 1 (1.1%) 44 (47.3%) 44 (47.3%) 4 (4.3%) 
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Severity of pulmonary hypertension: 
 
Severity Initial assessment 
After  2 months of 
treatment 
Grade 
No of 
patients 
Percent 
No of 
patients 
Percent 
MILD 18 17.3 35 38 
MODERATE 53 51.0 34 37 
SEVERE 33 31.7 24 26 
Total 104 100.0 93 100 
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 With treatment  51% patients with moderate PHT has reduced to 
37% 
 
 
82 
 
 
 
RA/RV DIMENSION: 
 With treatment there was no significant change in dimensions of 
RA and RV 
RA/RV 
DIMENSION Initial assessment After  2 months 
 
No of 
patients Percent 
No of 
patients Percent 
DILATED 90 86.5 79 84% 
NORMAL 11 10.6 11 12% 
RESTRICTED 3 2.9 3 3% 
Total 104 100.0 93 100 
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STATISTICAL ANALYSIS WITH PAIRED T TEST:  
 
 
Paired Samples Statistics 
  Mean N Std. 
Deviation 
Std. 
Error TTCx103 1.9368 93 0.44116 0.04575 
P<0.001 TTCx1031 2.1276 93 0.4334 0.04494 
MPV__fL 10.5631 93 0.61704 0.06398 
P<0.001 MPV_fL 10.3742 93 0.55284 0.05733 
PDW 16.7978 93 1.73387 0.17979 
P>0.05 PDW1 16.9054 93 1.62256 0.16825 
PLCR 27.5108 93 3.68751 0.38238 
P<0.001 PLCR1 26.8817 93 3.20614 0.33246 
mpap_0#61xPSAP2 46.3376 93 9.84252 1.02062 
P<0.001 mPAP 43.7225 93 9.60185 0.99567 
TAPSE 15.5054 93 1.65256 0.17136 
P<0.001 TAPSE1 15.9355 93 1.64056 0.17012 
EF_ 56.6667 93 9.19396 0.95337 
P<0.05 EF 57.7957 93 6.75915 0.70089 
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1.9368
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1.8
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1.9
1.95
2
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2.1
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Initial 2  months review 
TTCx103
Initial 2  months review 
 
 
10.56
10.37
10.25
10.3
10.35
10.4
10.45
10.5
10.55
10.6
Initial 2 months review 
MPV__fL
Initial 2 months review 
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43.72
42
42.5
43
43.5
44
44.5
45
45.5
46
46.5
47
Initial Assessment After 2 months
mPAP
Initial Assessment
After 2 months Review
 
With treatment the thrombocyte count and the platelet indices are 
altered as the mPAP decrease with treatment. 
CORRELATION OF  TTC WITH ECHO PARAMETERS: 
 PASP mPAP 
SYST
OLIC_
FN 
DIAST
OLIC_
FN 
EF_ 
PERICARDI
AL_EFFUSI
ONCLOT 
severi
ty 
TT
Cx1
03 
Pears
on 
Corr
elatio
n 
-.621** -.621** .263** -.052 -
.176 -.259
**
 
-
.622** 
Sig. 
(2-
tailed
) 
.000 .000 .007 .603 .074 .009 .000 
N 104 104 104 104 104 102 104 
Correlation is significant at the 0.01 level (2-tailed). 
Correlation is significant at the 0.05 level (2-tailed).  
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y = -24.57x + 120
R² = 0.385
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Scatter diagram for  TTc X10 3 vs PASP 
PASP Linear (PASP )
 
Thrombocyte count co relates with  mPASP, as mPASP increase 
TTC decreases 
y = -15.00x + 75.21
R² = 0.386
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Scatter diagram for  TTc X10 3 vs mpap
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CORRELATION OF MPV WITH ECHO PARAMETERS: 
 
 
 
 
 
 
PASP_4T
RV2RA 
mpap_0#6
1xPSAP2 
SYSTO
LIC_FN 
DIASTO
LIC_FN EF_ severity 
MPV
__fL 
Correl
ation 
Coeffi
cient 
.547** .562** -.314** -.027 -.005 .547** 
Sig. 
(2-
tailed) 
.000 .000 .001 .786 .959 .000 
N 104 104 104 104 104 104 
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y = 9.441x - 53.67
R² = 0.291
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Scatter diagram for MPV vs mpap
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MPV has significant correlation with PASP, mPAP, severity of 
pulmonary hypertension. MPV also has correlation with left ventricular 
systolic function. 
 
Correlation of P- LCR with echo parameters 
 
PASP_4
TRV2R
A 
mpap_0#6
1xPSAP2 
SYSTO
LIC_F
N 
DIAST
OLIC_F
N 
EF_ 
PERI
CARD
IAL_E
FFUSI
ONCL
OT 
sev
eri
ty 
PL
CR 
Pears
on 
Corre
lation 
.311** .312** -.190 -.062 .157 .002 .282** 
Sig. 
(2-
tailed
) 
.001 .001 .053 .532 .112 .983 .004 
N 104 104 104 104 104 102 104 
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 P-LCR correlates with PASP, mPAP, Severity of pulmonary 
hypertension. 
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Wilcoxon Signed Ranks Test:  
 
 With treatment the functional , severity of pulmonary hypertension 
and poor prognostic factors like pericardial effusiona an dclot improves 
without significant improvement in right atrial and ventricular 
dimensions. 
 
FUNCTIONAL_CLASS1 
- 
FUNCTIONAL_CLASS 
RARV_DIMENSION1 
- 
RARV_DIMENSION 
PERICARDIAL_EFFUSIONCLOT1 
- 
PERICARDIAL_EFFUSIONCLOT 
SEVERITY1 
- severity 
Z -7.488b -1.414b -3.354b -4.914b 
P 
VALUE .000 .157 .001 .000 
  
 
 
DISCUSSION 
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DISCUSSION 
 
 In our study we collected data of all newly diagnosed cases of 
pulmonary hypertension admitted in our hospital. Proper consent 
obtained after explaining the nature of study and investigations done. 
Patients willing to participate and accepted to come for review were 
enrolled in the study. All the enrolled patients were subjected to clinical 
history taking, general and systemic examination. Functional class 
accessed according to WHO grade used for pulmonary hypertension. 
Then blood for CBC and peripheral smear obtained and sent to process 
within 1 hour of collection. Bleeding and clotting time calculated. After 
taking ECG and chest X- ray, echocardiogram was done by cardiologist 
to access the pulmonary artery pressure using tricuspid regurgitation jet 
velocity there by pulmonary systolic artery pressure and mean pulmonary 
artery pressure were calculated. Right atrial and ventricular dimension 
were calculated. Tricuspid annular plane systolic excursion( TAPSE) 
value is calculated there by right ventricular dysfunction is assessed. Left 
ventricular systolic and diastolic function accessed. Ejection fraction 
calculated. Condition of valves were seen. Presence of pericardial 
effusion or clot were noted. 
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Aetiology: 
 In our study in 104 patients divided into 5 groups , pulmonary 
hypertension due to chronic lung disease was found to be the commonest 
cause. It accounts for 50 (48%) of total patients. This prevalence is in 
accordance to the previous studies in Indian population, while in western 
countries pulmonary hypertension due to cardiac causes forms the most 
common cause. 
 Among the chronic lung diseases causing pulmonary hypertension, 
COPD and old pulmonary tuberculosis form the most common cause 
accounting for 20%. May be due to increased prevalence of smoking and  
pulmonary tuberculosis in our population. 
 The second most common cause of pulmonary hypertension among 
5 groups is due to cardiac diseases accounting for 34%. Among them 
valvular diseases forms the major cause followed by systolic dysfunction. 
There could be significant overlap between group 2 and group 3 due the 
presence of similar risk factors and pathogenic mechanisms for both. 
Age: 
 Most common age at presentation being 41 to 50 yrs where 37 
patients has been diagnosed. Incidence is very low in younger population, 
in this age congenital and valvular heart disease predominates. 
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Sex: 
 In our study, prevalence of disease is more common in males 
56(53%), as opposed to greater  prevalence in female population may be 
due to more number of COPD cases occurring in males due to smoking. 
But the prevalence of pulmonary arterial hypertension due to idiopathic 
causes predominates in females. Occurrence of  connective tissue 
disorder leading to pulmonary hypertension is also seen in female 
population.  
Functional class: 
 Most of the patients admitted and diagnosed were having   WHO 
functional class 3 accounting for 43 (41%), as patients with milder 
functional class are not seeking medical attention or not getting 
hospitalised for evaluation and treatment. 
Severity of pulmonary hypertension: 
 Most of the patients diagnosed were having moderate degree of  
pulmonary hypertension . 53 patients had mPAP between 41 to 55 mmhg. 
This may be due to delay in early diagnosis of pulmonary hypertension. 
A delay of 2 to 5 years in diagnosis has been documented in various 
pulmonary hypertension registries. 
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Peripheral smear in PT: 
 Half of the patients with pulmonary hypertension had a normal 
peripheral smear study. Almost all patients with pulmonary arterial 
hypertension showed large platelets as compared to other groups. 
Thrombocytopenia is not a regular association seen in pulmonary 
hypertension. But when present indicates poor prognosis as evidenced by 
H.weaver, European heart journal aug 1, 2013. 
Valves in pulmonary hypertension: 
 Mild tricuspid regurgitation is commonly found valvular lesion. Its 
seen in 34 cases. Mild TR is mostly seen with moderate pulmonary 
hypertension causing Right atrial and right ventricular dilatation. As most 
patients presents late after development of moderate hypertension. 
Bleeding time and clotting time: 
 There was no significant difference in bleeding or clotting time 
among the different groups of pulmonary hypertension. No relation was 
found with the severity of pulmonary hypertension. 
Total thrombocyte count: 
 Is lower than normal in all groups of pulmonary hypertension 
ranging from 1.93 to 2.13x 103. patients with pulmonary arterial 
95 
 
 
hypertension had lower platelets than rest of the groups ranging from 1.67 
to 1.84x103. There is correlation between the platelet count and the 
PASP, mpAP and the severity of pulmonary hypertension. This study is 
in accordance to study by Guvenc et al, “comparing MPV values in 
various cause of pulmonary hypertension”, cardiology journal vol 19, 
2012. 
Platelet indices: 
Mean platelet volume: 
 There is a inverse relation between the number of platelets and the 
volume and distribution of platelets. In our study mean platelet volume is 
increased in all causes of pulmonary hypertension especially with 
pulmonary artery hypertension ranging from 11. 3 to 10.9  owing to the 
increased activation of platelets. This is seen in accordance to the study 
done by Guvenc et al, comparing the MPV in different cause of pH. 
Platelet distribution width: 
 As MPV, PDW is correlating with the severity of PH. It also 
correlates with the   presence of systolic function  as evidenced by Shu-
ichi fajita et al in paltelet indices and left ventricular function. 
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RA and RV Dilataion: 
 Presence of RA and RV dilataion is associated with moderate to 
severe grades of pulmonary hypertension. 
RV dysfunction: 
 As evidenced by decreased TAPSE of less than 16 is associated 
with severe pulmonary hypertension.  
Review of patients 2 months after treatment: 
 Most of the patients were attending the OPD for procuring free 
medications and hence review had lesser drop outs. 11 patients could not 
be reviewed as either they expired or lost follow up. Treatment for 
pulmonary hypertension given according to the groups of pulmonary 
hypertension they belong. Pulmonary arterial hypertension patients are 
treated according to the functional class they presented either with 
calcium channel blockers, endothelial receptor antagonist ,prostanoids.  
 Clinical assessment of pulmonary hypertension using WHO 
functional class showed improved after treatment with groups 1,2 and 3. 
Group 4 and 5 didn’t show improvement and worsened as surgery being 
the treatment option in group 4 and group 5 has multifactorial 
mechanisms and aetiology and poorer prognosis. 
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Severity of pulmonary hypertension with treatment: 
 51% of patients who were initially diagnosed as moderate PT, after 
treatment reduced to 37 %. 32% of patients with severe pulmonary 
hypertension reduced to 26% following treatment. The response to 
treatment was good with groups 2 and 3 compared to other groups. 
 Response in patients with moderate hypertension was found to be 
better than severe groups may be due to onset of irreversible changes and 
progression of disease. Patients needs to be diagnosed early and treatment 
initiated early for better response. 
The presence of right atrial and ventricular dilatation continues to 
be present after treatment. May be functional improvement occurs earlier 
than the anatomical changes takes place. Need for a longer treatment and 
follow up studies for the anatomical improvement to take place. 
 
 
 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 Pulmonary hypertension is the ultimate end result of alteration in 
pulmonary vasculature initiated and propagated by diverse pathologic 
mechanisms. Platelets are closely associated in both initiation and 
progression of disease. Platelet activation is associated with all groups of 
pulmonary hypertension.  
 Platelet indices are found to be altered in all causes of pulmonary 
hypertension. Thrombocytopenia is found to be a independent predictor 
of poor prognosis and mortality among patients with pulmonary 
hypertension 
 Most of the cases of pulmonary hypertension are diagnosed only 
after development of moderate hypertension. It should be suspected 
whenever patients present with overlapping symptoms of cardiac and 
respiratory illness. Especially among patients having high risk factors for 
pulmonary hypertension like connective tissue diseases, periodic 
screening with echocardiogram is indicated. 
 Echocardiographic evidence massive of RA/RV dilataion, TAPSE< 
16, pericardial effusion are associated with severe pulmonary 
hypertension and indicate a poorer prognosis. 
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 The difference in prevalence of PH among sexes and Aetiology in 
Indian subcontinent is noted. May be due the increased incidence of 
COPD due to smoking and post infectious sequel of tuberculosis which is 
rising. Most of the COPD patients presents with mild to moderate 
pulmonary hypertension. Extensive studies in pulmonary hypertension 
are conducted mostly in western population, the difference in aetiology 
and ethnicity in Indian population calls for a registry for pulmonary 
hypertension in India. 
            Treatment should be initiated after classification of patients to 
appropriate groups, as the aetiology and treatment is different for each 
group. The treatment response after development of severe hypertension 
is reduced. Earlier detection and early initiation of appropriate treatment 
is indicated. 
        Following treatment, Functional improvement occurs earlier than the 
anatomical improvement which calls for a longer duration of treatment 
and follow up. 
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ANNEXURES 
  
 ABBREVIATIONS 
 
CO  :  cardiac output 
mPAP :  mean pulmonary artery pressure 
BMPR2 :  bone morphogenic protein receptor 2 
RHC  :  right heart catherisation  
NIH  :  National institute of health 
PAWP :  pulmonary artery wedge pressure 
PVR  :  pulmonary vascular resistance 
TPR  : Total pulmonary resistance 
PAH  :  pulmonary aterial hypertension 
TAPSE : tricuspid annular plance systolic excursion 
CTEPH :  chronic thrombo embolic pulmonary hypertension 
 PROFORMA 
Assessment of Platelets in patient with pulmonary hypertension  
 
Name:     Age:    Sex:   
 
Patient ID:    Contact number:  Occupation: 
 
 
 NAME: 
 
 AGE: 
 
 SEX: 
 
 OP NUMBER: 
                                                       
                           
 PAST HISTORY – HYPERTENSION:              CAD:                  
PVD:            
 
                                 STROKE:                             RENAL 
DISEASE: 
 
PREGNANCY - YES:         NO:          N/A 
 
 CLINICAL EXAMINATION: 
 PALLOR: 
 ICTERUS: 
  CYANOSIS: 
 CLUBBING: 
 GENERALIZED LYMPAHADENOPATHY: 
 PEDAL EDEMA: 
 
 SYSTEMIC EXAMINATION:  CVS:                                                
 
                                                        RS: 
        
                                                        CNS:                                            
                                                  
                                                          PA:  
 
 
INVESTIGATIONS: 
 
1. Complete blood count  and  peripheral smear: 
 
2. Bleding test 
 
3. Clotting test 
 
4. ECG: 
 
 
 
 
 
 
 5. ECHOCARDIOGRAPHY FINDINGS: 
 
a) Pulmonary artery pressure assessement: 
 
TR jet velocity: 
 
PSAP:   4x (TR jet  velocity) 
mPAP: 
 severity: 
 
b) RV function assessment 
 
RA dimension 
 
RV dimension 
 
RV function     -    TAPSE  
 
c) LV function assessment 
 
LVID           (diastolic)           (systolic)             EF 
 
d) valves 
 
PE/Clot 
 
 
 
Others 
INFORMATION SHEET 
 
•   We are conducting a study on “Assessment of platelets in patients 
with pulmonary hypertension” among outpatients visiting Government 
General Hospital, Chennai and for that your sample may be valuable to 
us. 
 
 
• The purpose of this study is to study the platelet function and 
morphology in patients with pulmonary hypertension and its 
correlation with severity of pulmonary hypetension.  And also the 
effect of treatment of pulmonary hypertension on platelets 
 
• We are selecting certain cases and if your specimen is found 
eligible, we may be using your 4ml of blood sample to be collected in 
EDTA for platelet count and mean platelet volume . We also need to 
take an ECG and perform a 2D echocardiography and colour Doppler  
to assess the pulmonary hypertension. 
 
• The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will 
be shared. 
 
• Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise 
entitled. 
 
• The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
 
 
Signature of investigator                                           Signature of participant 
 
 
 
      Date: 
  
Muha;r;rp jfty; jh; ; ;; ; ;; ; ; s;;;; 
 
 EiuaPuypy; cs;s cah; ,uj;j mOj;jjpdhy; ghjpf;fg;gLk; 
Nehahspfspd; jl;lDf;fspy; Vw;gLk; khw;wk; gw;wpa Muha;r;rp 
 ,e;j Muha;r;rpapy; cq;fsplk; ,Ue;J 4.kp.yp ,uj;jk; vLj;J 
,uj;j mZf;fspd; ghpNrhjid> ,Uja RUs; glk;> khh;gf fjph;tPr;R> 
,Uja vjpnuhypg;G nra;ag;gLk;. ,uz;L khjk; kUj;Jt rpfpr;irf;F 
gpd;G kPz;Lk; midj;J ghpNrhjidfSk; nra;ag;gLk;. mjdhy; jq;fsJ 
Nehapd; Ma;twpf;ifNah my;yJ rpfpr;irNah ghjpg;G Vw;glhJ 
vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 KbTfis my;yJ fUj;Jf;fis ntspapLk;NghNjh my;yJ 
Muha;r;rpapd;NghNjh jq;fsJ ngaiuNah my;yJ milahsq;fisNah 
ntspapl khl;Nlhk; vd;gij njhptpj;Jf; nfhs;fpNwhk;. 
 ,e;j Muha;r;rpapy; gq;Nfw;gJ jq;fSila tpUg;gj;jpd;Nghpy; jhd; 
,Uf;fpwJ. NkYk; ePq;fs; ve;j NeuKk; ,e;j Muha;r;rpapypUe;J 
gpd;thq;fyhk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 
Muha;r;rpahsh; ifnahg;gk;  gq;Nfw;ghsh; ifnahg;gk; 
 
ehs;:   
,lk;: 
  
PATIENT CONSENT FORM 
 
 
Study Title : 
   Assessment of platelets in  
   patients with pulmonary hypertension” 
 
 
Study Centre :    Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to 
me in my own language ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological and biochemical tests. ❏ 
 
 
Signature/thumb impression    Signature of Investigator 
 
 
Patient’s Name and Address:    Study Investigator’s Name: 
 
 
Dr. V.GOVARDHINI 
 
 Muha;r;rp ; ;; ;; ; xg;Gjy; fbjk;; ; ;; ; ;; ; ; 
 
 Muha;r;rp ; ;; ;; ; jiyg;G:;;;  EiuaPuypy; cs;s cah; ,uj;j mOj;jjpdhy; P ; ; ; ; ; ;P ; ; ; ; ; ;P ; ; ; ; ; ;
ghjpf;fg;gLk; Nehahspfspd; jl;lDf;fspy; Vw;gLk; khw;wk; gw;wpa ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;
Muha;r;rp; ;; ;; ;  
 ,e;j Muha;r;rpapy; cq;fsplk; ,Ue;J 4.kp.yp ,uj;jk; vLj;J 
,uj;j mZf;fspd; ghpNrhjid> ,Uja RUs; glk;> khh;gf fjph;tPr;R> 
,Uja vjpnuhypg;G nra;ag;gLk;. ,uz;L khjk; kUj;Jt rpfpr;irf;F 
gpd;G kPz;Lk; midj;J ghpNrhjidfSk; nra;ag;gLk;. 
,e;j Muha;r;rpapd; tptuq;fSk; mjd; Nehf;fq;fSk; KOikahf 
vdf;F njspthf tpsf;fg;gl;lJ. 
vdf;F tpsf;fg;gl;l tp\aq;fis ehd; Ghpe;Jnfhz;L vdJ 
rk;kjj;ij njhptpf;fpNwd;. 
,e;j Muha;r;rpapy; gpwhpd; eph;ge;jkpd;wp vd; nrhe;j 
tpUg;gj;jpd;Nghpy; gq;F ngWfpd;Nwd;. ,e;j Muha;r;rpapy; ,Ue;J ehd; 
ve;NeuKk; gpd;thq;fyhk; vd;gijAk; mjdhy; ve;j ghjpg;Gk; Vw;glhJ 
vd;gijAk; ehd; Ghpe;Jnfhz;Nld;. 
ehd; vd;Dila Ra epidTld; kw;Wk; KO Rje;jpuj;JlDk; ,e;j 
kUj;Jt Muha;r;rpapy; vd;id Nrh;j;Jf;nfhs;s rk;kjk;. 
 
Muha;r;rpahsh; ifnahg;gk;  gq;Nfw;ghsh; ifnahg;gk; 
 
ehs;:   
,lk;: 
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1 24 F 36901 BRONCHIECTASIS/COPD3 3 1.03 11 19 38
LARGE 
PLATELE
TS 4 0" 3 30" 67.2 43 DILATED 12 N N 65 NORMALNO MODERATE 2 2 11 18 35 64 41 DILATED 14 N - 65 NORMALNO MODERATE
2 52 F 39427  OLD PT/COPD 3 3 1.67 11 18 35 NORMAL 3 30" 4 0" 70.5 45 DILATED 14 N N 63 NORMALNO MODERATE 2 2 10.3 20 28 67.2 43 DILATED 16 N N 65 NORMALNO MODERATE
3 50 F 39560 PAH-IDOPATHIC 1 4 1.5 12 19 36
LARGE 
PLATELE 4 30" 4 30" 73.9 47.1 DILATED 11 N N 60 TR MILDNO MODERATE 3 2 11 19 35 70.5 45 DILATED 11 N N 60 TR MILDNO MODERATE
4 65 F 40070 PAH-CTD 1 4 1.35 11 19 30
LARGE 
PLATELE
TS 4 0" 4 0" 88.3 55.8 DILATED 12 N N 55
TR 
MODR
ATE NO SEVERE 3 1.5 11.3 19 29 88.36 55.8 DILATED 12 N N 58 TR MILDNO SEVERE
5 45 M 40089 OLD PT/COPD 3 2 2.02 10 18 30 NORMAL 3 30" 4 30" 46.2 30.2 NORMAL 16 N N 65 NORMALNO MILD 1 2.4 10.3 18 32 43.56 28.5 NORMAL 16 N N 65 NORMALNO MILD
6 58 M 40156  OLD PT/COPD 3 4 0.94 11 20 38
THROMB
OCYTOPE
NIA 5 0" 4 0" 88.3 55.8 DILATED 16 N N 60 TR MILDMILD PESEVERE 3 1.7 11.5 19 35 88.36 55.8 DILATED 16 N N 60   TR MILDNO SEVERE
7 48 F 41835 VALVULAR HD 2 4 1.56 10 14 30 NORMAL 4 0" 5 30" 92.2 58.2 DILATED 17 N N 65 MS/MR NO SEVERE 3 1.7 9.8 14 28 88.4 55.8 DILATED 17 N N 65 MS MODERATENO SEVERE
8 52 M 41850  LV  SYS DYFN 2 4 2.46 9.9 12 20 NORMAL 3 30" 4 30" 88.4 55.8 DILATED 16 + N 30 MR MILD NO SEVERE 3 2.5 9.5 12 19 81 51.4 DILATED 16 + N 35 MR MILDNO MODERATE
9 46 M 42050 OLD PT/COPD 3 2 2.58 9 11 16 NORMAL 3 0" 4 30" 46.2 30.2 NORMAL 17 N N 65 NORMALNO MILD 2 2.7 9 12 15 46.24 30.2 NORMAL 17 N N 65 NORMALNO MILD
10 65 M 42506 OLD PT/COPD 3 3 1.98 11 13 28 NORMAL  3 0' 4 0" 81 51.4 DILATED 18 N N 50 NORMALNO MODERATE
11 37 M 42586 CTEPH 4 4 2.04 11 15 25 NORMAL 3 30" 5 30" 92.1 58.2 DILATED 14 N N 68 TR MILDNO SEVERE 4 2.5 10.5 16 28 88.36 55.8 DILATED 15 N N 65 TR MILDNO SEVERE
REVIEW AFTER 2 MTHS TREATMENT
HAEMOGRAM
RV  FUNCTION HAEMOGRAM
ECHOCARDIOGRAM
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12 35 F 42670 VALVULAR HD 2 2 2.5 9.5 16 26 NORMAL  4 0" 3 00" 40.9 27 NOMAL 17 N N 60 MS MODERATENO MILD 2 3.1 9.2 16 26 40.9 27 NORMAL 17 N N 60 MS MODERATENO MILD
13 40 M 32879 OLD PT/COPD 3 2 2.4 8.6 15 23 NORMAL 3 0" 3 30" 43.5 28.5 NORMAL 16 N N 65 NORMALNO MILD 2 2.7 8.6 15 24 40.9 27 NORMAL 17 N N 65 NORMALNO MILD
14 50 F 33056 ILD 3 3 1.46 11 16 28
LARGE 
PLATELE
TS 4 0" 4 0" 84.6 53.6 DILATED 15 N N 60 NORMALNO MODERATE 3 1.6 10 16 28 88.36 55.8 DILATED 15 N N 60 TR MILDNO SEVERE
15 46 M 33067 OLD PT/COPD 3 3 2.06 10 18 25 NORMAL 3 30" 4 30" 64 41 DILATED 17 N N 63 NORMALNO MODERATE 2 2.4 10.4 18 25 54.76 35.4 DILATED 17 N N 63 NORMAL NO MILD
16 24 F 33128 VALVULAR HD 2 4 1.6 11 17 28
LARGE 
PLATELE
TS 4 0" 4 0" 88.4 55.8 DILATED 15 N N 60 SEVERE MSNO SEVERE 3 1.8 10.5 17 28 81 51.41 DILATED 15 N N 60 MS SEVERENO MODERATE
17 68 M 33145 LV DAS DYFN 2 3 2.05 11 18 26 NORMAL 3 0" 4 30" 64 41.04 DILATED 17 N + 55 MODERATE MRNO MODERATE 2 2.4 10.6 18 27 54.76 35.4 DILATED 17 N + 55  MILD MRNO MILD
18 55 F 33209 OSA/ MORBID OBESITY3 4 1.39 11 18 29
LARGE 
PLATELE
TS 3 30" 4 0" 92.2 58.21 DILATED 15 N N 58 MILD TRMILD PESEVERE 4 1.6 11 18 27 88.36 55.8 DILATED 15 N N 55 MILD TRNO SEVERE
19 35 F 33245 ILD 3 2 2.56 11 15 26 NORMAL 4 0" 5 30" 70.6 45 DILATED 16 N N 60 NORMALNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
20 56 M 33450 BRONCHIECTASIS/COPD3 2 2.48 10 16 25 NORMAL 4 0" 4 30" 49 31.9 NORMAL 17 N N 60 normal NO MILD 2 2.7 9.9 16 26 46.2 30.2 NORMAL 17 N N 63 NORMALNO MILD
21 45 M 33560 VALVULAR HD 2 3 2.04 10 15 26 NORMAL 3 0" 4 0" 70.5 45 DILATED 16 N N 58 MS/MR NO MODERATE 3 2.5 10.2 15 24 64 41 DILATED 16 N N 60 MS/MR NO MODERATE
22 60 F 33659 OLD PT/COPD 3 4 1.95 11 18 28
LARGE 
PLATELE
 2 0" 5 30" 96 60.5 DILATED 16 N N 63 MILD TRMILD PESEVERE
23 35 F 33680 VSD 2 3 2.05 9.4 15 24 NORMAL 3 '0 4 0" 67.2 43 DILATED 17 N N 58 MILD MRNO MODERATE 2 2.5 9.4 16 25 64 41.04 DILATED 17 N N 58 MILD MRNO MODERATE
24 70 M 33760 OLD PT/COPD 3 3 1.97 11 18 26 NORMAL 4 30" 4 30" 64 41.04 DILATED 17 N N 55 normal NO MODERATE 2 2.5 10.5 18 27 60.84 39.11 DILATED 18 N N 58 NORMALNO MILD
25 26 F 33798 VALVULAR HD 2 2 2.67 9.8 15 21 NORMAL 3 30" 4 0" 43.6 28.5 NORMAL 18 N N 63 MODERATE MRNO MILD 2 2.6 9.4 16 20 40.96 27 NORMAL 18 N N 63 MODERATE MRNO MILD
26 38 M 33887 VALVULAR HD 2 3 2.85 9.7 16 22 NORMAL 3 0" 4 30" 46.2 30.2 NORMAL 18 N N 65 MODERATE MRNO MILD 3 2.9 9.5 16 21 43.56 28.5 NORMAL 18 N N 65 MODERATE MRNO MILD
27 55 F 33890 ILD 3 4 1.56 11 19 28 LARGE PLATELETS 2 0" 4 0" 92.2 58.21 DILATED 14 N N 55 MILD TRNO SEVERE 4 1.7 11 19 27 96.04 58.21 DILATED 14 N N 55 MODERATE TRNO SEVERE
28 66 M 43896  LV  SYS DYFN 2 4 2.08 11 18 24 LARGE PLATELETS3 0" 5 30" 67.2 43 DILATED 17 + N 28 MODEARTE MRCLOT+ MODERATE 3 2.2 10.5 18 25 57.76 37.23 DILATED 17 + N 35 MILD MRNO MILD
29 32 F 44675 VSD 2 3 2.2 11 18 23 NORMAL 3 30" 3 30" 70.6 45 DILATED 18 N N 58 VSDMILDTRNO MODERATE 2 2.3 10.4 18 23 64 41.04 DILATED 18 N N 58 VSDMILD TRNO MODERATE
30 56 F 44765 OSA/ MORBID OBESITY3 4 0.98 12 19 32 LARGE PLATELETS2 30" 4 0" 96 60.5 DILATED 14 N N 55 MODERATE MRMILD PESEVERE
31 45 M 44776 CTEPH 4 3 2.45 11 18 30 LARGE PLATELETS3 0" 4 30" 67.2 43 DILATED 16 N N 60 MILD MRNO MODERATE 2 2.5 10.5 18 29 67.24 43 DILATED 16 N N 60 MILD TRNO MODERATE
LOST REVIEW PATIENT EXPIRED
LOST  REVIEW PATIENT EXPIRED
32 40 F 44786 PAH-CTD 1 4 1.56 11 19 32 LARGE PLATELETS2 30" 4 0" 92.2 58.21 DILATED 14 N N 55 MODERATE MRNO SEVERE 3 1.7 11.3 18 30 92.16 58.21 DILATED 14 N N 55 MODERATE TRNO SEVERE
33 58 M 44877 OLD PT/COPD 3 3 2.13 11 17 30 LARGE PLATELETS3 0" 4 30" 64 41.04 DILATED 16 N N 60 MILD TRNO MODERATE 2 2.3 10.7 17 28 57.7 37.2 DILATED 15 N N 60 NORMALNO MILD
34 34 F 43986 VALVULAR HD 2 3 1.96 10 15 25 LARGE PLATELETS4 0" 4 0" 64 41 NORMAL 17 N N 63 MS MODERATENO MODERATE 2 2.1 10.2 15 25 60.8 39.1 NORMAL 17 N N 53 MS MODERATENO MILD
35 45 M 43994 LV DAS DYFN 2 3 1.86 10 18 28 NORMAL 3 30" 5 30" 70.6 45 DILATED 17 N + 55 MR MILDNO MODERATE 2 2 10.3 16 25 64 41.04 DILATED 17 N + 55 MILD MRNO MODERATE
36 45 F 44009 PAH-IDOPATHIC 1 4 1.45 11 19 30 LARGE PLATELETS4 0" 4 30" 92.1 58.2 DILATED 13 N N 65 MILD TRNO SEVERE 3 1.5 11 19 28 88.36 55.8 DILATED 15 N N 65 MILD TRNO SEVERE
37 60 F 44150 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 3 30" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
38 58 M 44258 OLD PT/COPD 3 4 2.06 11 18 28 LARGE PLATELET4 0" 3 30" 88.4 55.8 DILATED 15 N N 55 MILD TRNO SEVERE 3 2.2 10.5 17 27 81 51.4 DILATED 17 N N 60 MILD TRNO MODERATE
39 62 M 44568 LV  SYS DYFN 2 2 2.47 9.9 15 27 NORMAL 4 30" 4 0" 46.2 30.2 DILATED 15 + N 40 MILD MRNO MILD 2 2.6 9.9 15 25 43.5 28.5 DILATED 18 + N 45 NORMALNO MILD
40 48 M 44598 BRONCHIECTASIS/COPD3 3 1.89 11 15 26 NORMAL 4 0" 4 30" 70.6 45 DILATED 16 N N 63 NORMALNO MODERATE 2 2.1 10.4 16 26 60 39.1 DILATED 16 N N 65 NORMALNO MILD
41 29 F 44678 PAH-HIV 1 4 1.08 11 19 30 LARGE PLATELET5 30" 4 0" 92.2 58.21 DILATED 14 N N 60 MILD TRNO SEVERE 3 1.1 10.7 19 29 88.36 55.8 DILATED 14 N N 60 MILD TRNO SEVERE
42 39 M 44769 VALVULAR HD 2 3 2.45 11 17 27 NORMAL  40" 4 30" 81 51.41 DILATED 15 N N 65 MS MODERATENO MODERATE 2 2.6 10.5 18 27 64 41 DILATED 16 N N 65 MS MODERATENO MODERATE
43 50 M 44890 OLD PT/COPD 3 2 1.98 11 18 25 LARGE PLATELET4 30" 4 0" 43.6 28.5 DILATED 17 N N 65 NORMALNO MILD 2 2 10.5 16 25 40.96 27 NORMAL 17 N N 65 NORMALNO MILD
44 40 M 44950 OLD PT/COPD 3 2 2.15 11 17 27 NORMAL 3 30" 5 30" 41 27 NORMAL 18 N N 60 NORMALNO MILD
45 26 M 46796 ASD 2 3 2.34 9.6 17 26 NORMAL 3 0" 4 0" 67.2 43 DILATED 18 N N 58 VSDMILDTRNO MODERATE 2 2.4 9.5 17 26 64 41.04 DILATED 18 N N 60 VSDMILD TRNO MODERATE
46 42 F 46901 BRONCHIECTASIS/COPD3 3 2.05 11 18 27 LARGE PLATELETS3 0" 4 30" 70.5 45 DILATED 17 N N 60 NORMALNO MODERATE 2 2.1 10.5 18 27 60.8 39.1 DILATED 17 N N 60 NORMALNO MILD
47 52 F 49427  OLD PT/COPD 3 2 2.13 11 17 30 LARGE PLATELETS3 0"  3 0' 64 41.04 DILATED 16 N N 60 MILD TRNO MODERATE 2 2.3 10.7 17 28 57.7 37.2 DILATED 15 N N 60 NORMALNO MILD
48 45 F 49560 PAH-IDOPATHIC 1 3 1.56 11 19 32 LARGE PLATELETS2 30" 4 30" 92.2 58.21 DILATED 14 N N 55 MODERATE MRNO SEVERE 3 1.7 11.3 18 30 92.16 58.21 DILATED 14 N N 55 MODERATE TRNO SEVERE
49 50 F 50070 PAH-CTD 1 3 2.56 11 15 26 NORMAL 4 0" 3 30" 70.6 45 DILATED 16 N N 60 NORMALNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
50 45 M 51089 OLD PT/COPD 3 2 1.97 11 18 26 NORMAL 4 30" 4 00" 64 41.04 DILATED 17 N N 55 normal NO MODERATE 2 2.5 10.5 18 27 60.84 39.11 DILATED 18 N N 58 NORMALNO MILD
51 58 M 53156  OLD PT/COPD 3 3 1.98 11 13 28 NORMAL  3 0' 4 0" 81 51.4 DILATED 18 N N 50 NORMALNO MODERATE
52 58 M 54994 LV  SYS DYFN 2 3 2.46 9.9 15 27 NORMAL 4 30" 4 30" 46.2 30.2 DILATED 15 + N 40 MILD MRNO MILD 2 2.6 9.9 15 25 43.5 28.5 DILATED 18 + N 45 NORMALNO MILD
LOST REVIEW
LOST  REVIEW 
53 48 F 54009 PAH-IDOPATHIC 1 4 1.5 12 19 36
large 
platelets 4 30"  3 0' 73.9 47.1 dilated 11 N N 60 TR mild NO moderate 3 2 11 19 35 70.5 45 dilated 11 N N 60 TR mild NO moderate
54 56 F 54150 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 4 30" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
55 75 M 54268 OLD PT/COPD 3 4 2.06 11 18 28 LARGE PLATELET4 0" 3 30" 88.4 55.8 DILATED 15 N N 55 MILD TRNO SEVERE 3 2.2 10.5 17 27 81 51.4 DILATED 17 N N 60 MILD TRNO MODERATE
56 62 M 54578  LV  SYS DYFN 2 2 1.86 10 18 28 NORMAL 3 30" 3 '0 70.6 45 DILATED 17 + N 58 MR MILDNO MODERATE 2 2 10.3 16 25 64 41.04 DILATED 17 + N 33 MILD MRNO MODERATE
57 47 M 54598 OLD PT/COPD 3 2 2.13 11 17 29 LARGE PLATELETS3 30" 4 30" 64 41.04 DILATED 16 N N 60 MILD TRNO MODERATE 2 2.3 10.7 17 28 57.7 37.2 DILATED 15 N N 60 NORMALNO MILD
58 36 F 56798 VALVULAR HD 2 2 2.15 11 17 27 NORMAL 3 30" 4 30" 41 27 DILATED 18 N N 60 MODERATE MRNO MILD
59 24 M 57887 VALVULAR HD 2 3 1.96 10 15 25 LARGE PLATELETS4 0" 4 0" 64 41 NORMAL 17 N N 63 MS MODERATENO MODERATE 2 2.1 10.2 15 25 60.8 39.1 NORMAL 17 N N 53 MS MODERATENO MILD
60 52 F 58890 ILD 3 4 1.56 11 19 28 LARGE PLATELETS 2 0" 4 30" 92.2 58.21 DILATED 14 N N 55 MILD TRMILD PESEVERE 4 1.7 11 19 27 96.04 58.21 DILATED 14 N N 55 MODERATE TRNO SEVERE
61 68 M 63896  LV  SYS DYFN 2 4 2.46 9.9 12 20 NORMAL 3 30" 4 0" 88.4 55.8 DILATED 16 + N 28 MR MILD NO SEVERE 3 2.5 9.5 12 19 81 51.4 DILATED 16 + N 35 MR MILDNO MODERATE
62 32 M 64675 VSD 2 3 2.05 9.4 15 24 NORMAL 3 '0 5 30" 67.2 43 DILATED 17 N N 58 VSD MILD MRNO MODERATE 2 2.5 9.4 16 25 64 41.04 DILATED 17 N N 58 VSD MILD MRNO MODERATE
63 46 F 64765 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 5 00" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
64 45 M 64776 CTEPH 4 4 1.38 11 17 27 LARGE PLATELETS4 30" 4 30" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
65 40 F 64786 PAH-CTD 1 3 2.56 11 15 26 NORMAL 4 0" 3 30" 70.6 45 DILATED 16 N N 60 NORMALNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
66 68 F 64568  LV  SYS DYFN 2 2 2.36 9.9 15 27 NORMAL 4 30" 4 0" 46.2 30.2 DILATED 15 + N 28 MILD MRNO MILD 2 2.6 9.9 15 25 43.5 28.5 DILATED 18 + N 45 NORMALNO MILD
67 48 F 64598 OLD PT/COPD 3 3 1.89 11 15 26 NORMAL 4 0" 4 30" 70.6 45 DILATED 16 N N 63 NORMALNO MODERATE 2 2.1 10.4 16 26 60 39.1 DILATED 16 N N 65 NORMALNO MILD
68 49 M 64678 PAH-CTD 1 4 1.08 11 19 30 LARGE PLATELET5 30" 4 0" 92.2 58.21 DILATED 14 N N 60 MILD TRNO SEVERE 3 1.1 10.7 19 29 88.36 55.8 DILATED 14 N N 60 MILD TRNO SEVERE
69 49 M 64769 VALVULAR HD 2 3 2.45 11 17 27 NORMAL  40" 4 30" 81 51.41 DILATED 15 N N 65 MS MODERATENO MODERATE 2 2.6 10.5 18 27 64 41 DILATED 16 N N 65 MS MODERATENO MODERATE
70 50 M 64890 OLD PT/COPD 3 2 1.98 11 18 25 LARGE PLATELET4 30" 4 0" 43.6 28.5 DILATED 17 N N 65 NORMALNO MILD 2 2 10.5 16 25 40.96 27 NORMAL 17 N N 65 NORMALNO MILD
71 45 F 64950 PAH-IDOPATHIC 3 2 2.15 11 17 27 NORMAL 3 30" 5 30" 41 27 NORMAL 18 N N 60 NORMALNO MILD
72 46 M 66796 ASD 2 3 2.34 9.6 17 26 NORMAL 3 0" 4 30" 67.2 43 DILATED 18 N N 58 VSDMILDTRNO MODERATE 2 2.4 9.5 17 26 64 41.04 DILATED 18 N N 60 VSDMILD TRNO MODERATE
73 48 M 67009 OTHERS-SARCOIDOSIS1 4 1.5 12 19 36
large 
platelets 4 30" 4 0" 73.9 47.1 dilated 11 N N 60 TR mild NO moderate 3 2 11 19 35 70.5 45 dilated 11 N N 60 TR mild NO moderate
74 56 F 67150 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 3 30" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
75 75 M 68268 BRONCHIECTASIS/COPD3 4 2.06 11 18 28 LARGE PLATELET4 0" 4 30" 88.4 55.8 DILATED 15 N N 55 MILD TRNO SEVERE 3 2.2 10.5 17 27 81 51.4 DILATED 17 N N 60 MILD TRNO MODERATE
76 52 M 68578  LV DAS DYFN 2 2 2.26 10 18 27 NORMAL 3 30" 4 0" 64 41.04 DILATED 17 N + 28 MR MILDNO MODERATE 2 2 10.3 16 25 64 41.04 DILATED 17 N + 55 MILD MRNO MODERATE
77 47 M 68598 OLD PT/COPD 3 2 2.13 11 17 29 LARGE PLATELETS3 30" 3 30" 64 41.04 DILATED 16 N N 60 MILD TRNO MODERATE 2 2.3 10.7 17 28 57.7 37.2 DILATED 15 N N 60 NORMALNO MILD
LOST  REVIEW 
LOST  REVIEW 
78 36 F 68798 OLD PT/COPD 3 3 2.15 11 17 27 LARGE PLATELETS3 30" 2 30" 41 27 DILATED 18 N N 60 NORMALNO MILD
79 70 M 69659 OLD PT/COPD 3 4 1.95 11 18 28
LARGE 
PLATELE
 2 0" 4 0" 96 60.5 DILATED 16 N N 63 MILD TRNO SEVERE
80 25 F 69680 VSD 2 3 2.05 9.4 15 24 NORMAL 3 '0 3 '0 67.2 43 DILATED 17 N N 58 MILD MRNO MODERATE 2 2.5 9.4 16 25 64 41.04 DILATED 17 N N 58 MILD MRNO MODERATE
81 70 M 69760 OLD PT/COPD 3 3 1.97 11 18 26 NORMAL 4 30" 4 30" 64 41.04 DILATED 17 N N 55 normal NO MODERATE 2 2.5 10.5 18 27 60.84 39.11 DILATED 18 N N 58 NORMALNO MILD
82 50 F 69762 LV DAS DYFN 2 4 2.02 11 16 25 NORMAL 3 30" 3 00" 64 41 RESTRICTED 16 N + 55 NORMALPE MODERATE 3 2.1 10.5 16 25 57.7 37.2 RESTRICTED 16 N + 55 NORMALPE+ MILD
83 36 M 69780 CHEST DEFORMITIES 3 3 1.38 11 17 27 LARGE PLATELETS4 30" 4 30" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
84 45 M 69880 LV DAS DYFN 2 4 1.45 11 16 27 LARGE PLATLETS3 0" 3 30" 64 41 RESTRICTED 17 N + 55 NORMALPE MODERATE 3 1.8 10.7 15 27 60.84 39.11 RESTRICTED 17 N + 55 NORMALPE+ MILD
85 42 F 69901 CHEST DEFORMITIES 3 3 2.05 11 18 27 LARGE PLATELETS3 0" 4 0" 70.5 45 DILATED 17 N N 60 NORMALNO MODERATE 3 2.1 10.5 18 27 70.6 45 DILATED 17 N N 60 NORMALNO MODERATE
86 52 F 69427  OLD PT/COPD 3 2 2.13 11 17 30 LARGE PLATELETS3 0" 3 '0 64 41.04 DILATED 16 N N 60 MILD TRNO MODERATE 2 2.3 10.7 17 28 57.7 37.2 DILATED 15 N N 60 NORMALNO MILD
87 45 F 69560 PAH-CTD 1 3 1.56 11 19 32 LARGE PLATELETS2 30" 4 30" 92.2 58.21 DILATED 14 N N 55 MODERATE MRSEVERE 3 1.7 11.3 18 30 92.16 58.21 DILATED 14 N N 55 MODERATE TRNO SEVERE
88 50 F 70070 PAH-HIV 1 3 2.56 12 18 30 NORMAL 4 0" 3 30" 70.6 45 DILATED 16 N N 60 NORMALNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
89 36 M 72675 VSD 2 3 2.05 9.4 15 24 NORMAL 3 '0 4 30" 67.2 43 DILATED 17 N N 58 VSD MILD MR MODERATE 2 2.5 9.4 16 25 64 41.04 DILATED 17 N N 58 VSD MILD MRNO MODERATE
90 36 M 72765 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 4 00" 96 60.6 DILATED 14 N N 58 MILD TRNO SEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
91 32 M 73675 PDA 2 3 2.05 9.4 15 24 NORMAL 3 0" 4 30" 67.2 43 DILATED 17 N N 58 NORMALNO MODERATE 2 2.5 9.4 16 25 64 41.04 DILATED 17 N N 58 NORMALNO MODERATE
92 46 F 73765 OSA/ MORBID OBESITY3 4 1.38 11 17 30 LARGE PLATELETS4 30" 5 00" 96 60.6 DILATED 14 N N 58 MILD TRPE SEVERE 3 1.5 10.8 18 27 92.16 58.21 DILATED 15 N N 58 MILD TRNO SEVERE
93 45 M 73776 CTEPH 4 4 1.58 11 18 29 LARGE PLATELETS4 30" 5 30" 88.3 55.8 DILATED 15 N N 55 MILD TRNO SEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 55 MILD TRNO SEVERE
94 24 F 73786 OTHERS-MPD 1 3 2.56 11 15 26 NORMAL 4 0" 4 00" 70.6 45 DILATED 16 N N 60 NORMALNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
95 46 M 74150 OSA/ MORBID OBESITY3 4 1.38 11 17 27 LARGE PLATELETS4 30" 4 0" 96 60.6 DILATED 14 N N 58 MILD TRMILD PESEVERE 3 1.5 10.6 18 27 88.36 55.8 DILATED 15 N N 58 MILD TRNO SEVERE
96 35 M 74268 OLD PT/COPD 3 4 1.89 11 18 28 LARGE PLATELET4 0" 3 30" 88.4 55.8 DILATED 15 N N 55 MILD TRNO SEVERE 3 2.2 10.5 17 27 81 51.4 DILATED 17 N N 60 MILD TRNO MODERATE
97 62 M 74578  LV  SYS DYFN 2 2 1.96 11 18 28 NORMAL 3 30" 4 30" 70.6 45 DILATED 17 + N 28 MR MILDCLOT+ MODERATE
98 40 F 74786 ILD 3 3 2.56 11 15 30 NORMAL 4 0" 4 0" 70.6 45 DILATED 16 N N 60 MILD TRNO MODERATE 3 2.6 10.5 17 28 70.56 45 DILATED 16 N N 60 MILD TRNO MODERATE
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99 58 F 74568  LV  SYS DYFN 2 2 2.46 9.9 15 27 NORMAL 4 30" 3 30" 46.2 30.2 DILATED 15 + N 28 MILD MRCLOT+ MILD 2 2.6 9.9 15 25 43.5 28.5 DILATED 18 + N 45 NORMALNO MILD
100 56 M 74598 CHEST DEFORMITIES 3 3 1.89 11 18 29 LARGE PLATELETS4 0" 4 0" 70.6 45 DILATED 16 N N 63 DILATEDNO MODERATE 2 2.1 10.4 16 26 60 39.1 DILATED 16 N N 65 NORMALNO MILD
101 58 M 75156  OLD PT/COPD 3 3 1.98 11 13 28 NORMAL  3 0' 4 0" 81 51.4 DILATED 18 N N 50 NORMALNO MODERATE
102 60 F 75994 LV  SYS DYFN 2 3 2.25 9.9 15 27 NORMAL 4 30" 4 30" 46.2 30.2 DILATED 15 + N 28 MILD MRNO MILD 2 2.6 9.9 15 25 43.5 28.5 DILATED 18 + N 45 NORMALNO MILD
103 48 M 75009 PAH-HIV 1 4 1.5 12 19 36
large 
platelets 4 30"  3 0' 73.9 47.1 dilated 11 N N 60 TR mild NO moderate 3 2 11 19 35 70.5 45 DILATED 11 N N 60 TR MILDNO MODERATE
104 35 F 75880 LV DAS DYFN 2 4 1.45 11 16 27 LARGE PLATLETS3 0" 3 30" 64 41 RESTRICTED 17 N + 55 NORMALPE MODERATE 3 1.8 10.7 15 27 60.84 39.11 RESTRICTED 17 N + 55 NORMALPE+ MILD
LOST REVIEW
